| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Medtronic plc.$83.87
+1.48 (+1.8%)
B 70Pipeline Score MedTech · Commercial
Market Cap
100.91 B
EPS
3.60
P/E Ratio
21.94 $
Value Trade
1.57 B
SEC Financials
Q2 2026Dilution Risk
Revenue
36.36 B
R&D Expenses
2.87 B
Operating CF
7.33 B
Total Assets
93.03 B
Total Liabilities
42.96 B
Equity
49.46 B
D/E Ratio
12,345
2.08 %
Week
-5.19 %
1 Month
-19.12 %
3 Month
-21.12 %
6 Month
-38.26 %
5 Year
24,973.61 %
All Time
Cash Data
Cash Position
9.22 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Jun 18, 2026
Overview
Volume
7.19 M
52 Week Range
74.40 - 106.33
% held by Insiders
0.1 %
% held by Institutions
90.06 %
Enterprise Value
120.81 B
Total Shares
1.28 B
Short %
1.44 %
Float Shares
1.28 B
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Medtronic plc.
780Total events
12Upcoming
331Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 12
Event history 768
Q3 2026
Jun 3, 2026
▲Quarterly UpdateCorporate
Medtronic reports Q4 FY26 revenue of $9.8B, GAAP EPS $0.96, non-GAAP EPS $1.55
Jun 3, 2026
▲Partnership / LicenseCorporate
Medtronic announces strategic investments in Beluga Medical and CardioACC for ICE catheter technologies
Jun 3, 2026
●NDA SubmissionRegulatory Filing
510(k) filings for Hugo RAS system in general surgery and gynecologic specialties
general surgery and gynecological proceduressource ↗
Jun 3, 2026
●NDA SubmissionRegulatory Filing
510(k) filing for LigaSure RAS Maryland instrument on Hugo RAS system
Jun 3, 2026
▲FDA Filing AcceptedRegulatory Filing
FDA clearance for ProGrip Advanced mesh for robotic-assisted ventral hernia repair
robotic-assisted ventral hernia repairsource ↗
Jun 3, 2026
▲Enrollment CompleteTrial
Enrollment completed in Embrace Gynecology IDE study for Hugo RAS system
gynecologic proceduressource ↗
Jun 3, 2026
●NDA SubmissionRegulatory Filing
Filed submission to U.S. FDA for Hugo RAS for general surgery and gynecologic indications
general surgery and gynecologicsource ↗
Jun 3, 2026
Jun 3, 2026
▲FDA ApprovalFDA Decision
Secured FDA Clearance for Spine, Cranial and ENT indications for Stealth AXiS Surgical System
Spine, Cranial and ENTsource ↗
Jun 3, 2026
▲EU ApprovalEx-US Regulatory
CE Mark for Spine and Cranial indications for Stealth AXiS Surgical System
Spine and Cranialsource ↗
Drug Pipeline Intelligence
B70
Pipeline Score $13.8B
Pipeline ValueValuation Signal
16
Drugs Scored0.5x
rNPV / MCap Top 94%
Large Pharma (rank 56 of 911)
Percentile RankMedtronic plc. holds a solid B-grade pipeline (70/100), with $13.8B risk-adjusted pipeline value, led by Closed loop with sensor and Insulin in Type 1 Diabetes (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Closed loop with sensor and Insulin Small molecule | Type 1 Diabetes | Phase 2 | NCT01755416 | 43% | $4.8B | COMPLETED | 18 | - | - | Jan 1, 2015 | - | Aug 21, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Sphere-9 catheter | recurrent sustained monomorphic ventricular tachycardia (VT) | Preclinical | 2026-04-25 | In a six-month follow-up of patients treated with the Sphere-9 catheter for recurrent sustained monomorphic ventricular tachycardia, 65.5% remained free from VT recurrence, indicating promising efficacy in this early feasibility study. Read More | Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic... Read More | |
Sphere-9 catheter | recurrent sustained monomorphic ventricular tachycardia (VT) | Preclinical | 2026-04-25 | In a six-month follow-up of patients treated with the Sphere-9 catheter for recurrent sustained monomorphic ventricular tachycardia, 65.5% remained free from VT recurrence, indicating promising efficacy in this early feasibility study. Read More | Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic... Read More | |
Sphere-9 catheter | recurrent sustained monomorphic ventricular tachycardia (VT) | Preclinical | 2026-04-25 | In a six-month follow-up of patients treated with the Sphere-9 catheter for recurrent sustained monomorphic ventricular tachycardia, 65.5% remained free from VT recurrence, indicating promising efficacy in this early feasibility study. Read More | Medtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MDT
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MDT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-28 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-28 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-28 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MDTMedtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
Medtronic has successfully acquired Scientia Vascular for $550 million, enhancing its neurovascular product portfolio. The integration of Scientia's access technologies aims to simplify complex procedures and improve efficiency for physicians. This strategic acquisition is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27 and accretive thereafter.
Read more →MDT▲ +5.7%on this news
Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
Medtronic has submitted 510(k) filings to expand its Hugo robotic-assisted surgery system into general and gynecologic specialties in the U.S. The company also announced FDA clearance for ProGrip Advanced mesh for robotic-assisted ventral hernia repair. Additionally, enrollment is complete for the Embrace Gynecology IDE study, evaluating the Hugo system's safety and effectiveness in gynecologic procedures.
Read more →MDT▲ +5.7%on this newsshared move
Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
Medtronic plc reported strong financial results for Q4 and FY26, achieving a 9.9% revenue increase in Q4 and an 8.4% increase for the fiscal year, marking the highest growth in a decade. Key drivers included significant growth in Cardiac Ablation Solutions and a successful launch of new products. The company also announced an increase in its dividend, reflecting confidence in future growth.
Read more →MDT▲ +5.7%on this newsshared move
Medtronic announces strategic investments to support future expansion of cardiac ablation portfolio as physician demand for Affera™ technologies broadens
Medtronic has announced strategic investments in two companies developing intracardiac echocardiography (ICE) technologies to enhance its cardiac ablation portfolio. These investments aim to integrate ICE into the Affera mapping and ablation system, reflecting the growing demand for advanced electrophysiology tools. The move is part of Medtronic's strategy to strengthen its leadership in the cardiac ablation market.
Read more →MDT▲ +5.7%on this newsshared move
Medtronic reports fourth quarter and full year fiscal 2026 results delivers highest annual revenue growth in 10 years Disciplined execution and portfolio strength position Medtronic for
Medtronic reported significant financial results for fiscal year 2026, achieving an 8.4% revenue growth, the highest in a decade. The company's fourth quarter revenue reached $9.8 billion, exceeding guidance with a notable 9.9% increase. Strong performance in key areas such as Cardiac Ablation and Cardiovascular contributed to the growth, and the company announced a quarterly dividend increase to $0.72 per share. However, concerns remain regarding a decrease in non-GAAP operating margins and the potential impact of tariffs on future profits.
Read more →MDT/C O R R E C T I O N -- Medtronic plc/ In the news release, "Medtronic Singapore partners with Society of Colorectal Surgeons to strengthen surgical training", issued on May 25 2026 by...
Medtronic Singapore has partnered with the Society of Colorectal Surgeons to enhance surgical training through a Memorandum of Understanding. The collaboration will focus on structured training programs and workshops to support surgeons at various career stages. This initiative aims to keep surgeons updated with evolving techniques in colorectal surgery, fostering closer ties between clinicians and industry partners.
Read more →MDTMedtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain
Medtronic has announced its intent to acquire SPR Therapeutics for approximately $650 million. This acquisition aims to enhance Medtronic's Neuromodulation portfolio by incorporating SPR's temporary peripheral nerve stimulation technology, which provides effective pain relief for chronic pain sufferers. The deal is expected to close in the first half of Medtronic's Fiscal Year 2027, pending regulatory approvals.
Read more →MDTOrchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
Orchestra BioMed reported strong financial results for Q1 2026, highlighting advancements in its cardiovascular pipeline, particularly for AVIM Therapy and Virtue SAB. The company is on track with its BACKBEAT Trial, with expected regulatory submissions by Medtronic. The collaboration with Medtronic positions Orchestra BioMed favorably in the market.
Read more →MDTMedtronic announces CE Mark for Stealth AXiS™ surgical system Medtronic, a global leader in healthcare technology, has received CE mark for the Stealth AXiS™ surgical system, a next-generation platform that...
Medtronic has announced that it has received a CE mark for its Stealth AXiS surgical system, which integrates planning, navigation, and robotics for enhanced surgical procedures. This next-generation platform is designed for both spine and cranial applications, offering advanced capabilities such as real-time anatomical visualization and AI-powered tractography. The achievement of CE mark follows previous FDA clearances, showcasing Medtronic's commitment to innovation and expanding access to advanced surgical technologies across Europe.
Read more →MDTMedtronic announces key Affera™ clinical study milestones for Sphere-9™ and Sphere-360™ catheters as global adoption continues HRS late-breaking data: Interim results highlight six-month outcomes for patients treated with the Sphere-9 catheter for sustained monomorphic...
Medtronic has announced important progress for its Affera family of technologies aimed at treating cardiac arrhythmias. Positive interim results from an early feasibility study show that 65.5% of patients treated with the Sphere-9 catheter remained free from ventricular tachycardia (VT) recurrence six months post-treatment. The FDA has granted Breakthrough Device Designation for the Sphere-9, providing an expedited pathway for its development. Additionally, the company is expanding its clinical trials to include a wider range of patients and is reporting successful outcomes for its Sphere-360 catheter in related studies.
Read more →MDTOrchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed announced two presentations on AVIM Therapy at the HRS 2026 Annual Meeting. The therapy aims to treat hypertensive heart disease by significantly reducing blood pressure without relying on additional medications. Key data from the MODERATO II trial highlighted its effectiveness, showing substantial improvements in blood pressure control for patients. The company anticipates further results from ongoing pivotal trials.
Read more →MDTMedtronic statement on unauthorized system access
Medtronic announced that an unauthorized party gained access to data in some of its corporate IT systems. The company has confirmed that there is no identified impact on its products, patient safety, or operational capabilities. Following the breach, Medtronic activated incident response protocols and engaged cybersecurity experts to investigate and remediate the situation. While they have not detected a material impact on business operations, they are actively working to identify any accessed personal information.
Read more →MDTMedtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease
Medtronic has completed its acquisition of CathWorks for $585 million, enhancing its cardiovascular portfolio. The CathWorks FFRangio System offers a non-invasive method for assessing coronary artery disease using AI technology. This acquisition follows a successful partnership and aims to improve patient care and outcomes in interventional cardiology.
Read more →MDTMedtronic to announce financial results for its fourth quarter and full fiscal year 2026
Medtronic plc has announced that it will release its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026. The announcement includes details about the timing of the news release and a video webcast to discuss the results. The company highlights its commitment to healthcare innovation and addressing significant health challenges.
Read more →MDTMedtronic Receives FDA Clearance for Stealth AXiS™ Surgical System for Cranial and ENT Procedures
Medtronic has received FDA clearance for its Stealth AXiS™ surgical system, designed for cranial and ENT procedures. This system integrates advanced navigation, robotics, and AI capabilities to enhance surgical precision and efficiency. The platform aims to support surgeons with real-time insights and improved workflows, marking a significant advancement in surgical technology.
Read more →MDTMedtronic and Merit Medical Systems enter into agreement to offer new, FDA-cleared ViaVerte™ system, a basivertebral nerve ablation treatment for chronic vertebrogenic lower-back pain
Medtronic has entered a distribution agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte™ system, a minimally invasive treatment for chronic vertebrogenic lower back pain. This system features a physician-controlled steerable mechanism for precise nerve targeting. The agreement enhances Medtronic's pain interventions portfolio and aims to provide patients with more effective treatment options.
Read more →MDTMedtronic OmniaSecure™ defibrillation lead is the first lead of its kind to receive FDA approval for conduction system pacing
Medtronic has received FDA approval for its OmniaSecure™ defibrillation lead, now indicated for placement in the left bundle branch area for conduction system pacing. This lead is the first of its kind and is designed to enhance patient outcomes by mimicking the heart's natural physiology. The approval is supported by positive clinical trial data demonstrating high success and low complication rates.
Read more →MDTMedtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care Medtronic today announced its entry into a definitive agreement to acquire Scientia Vascular, a company with critical, innovative technology across...
Medtronic has entered into a definitive agreement to acquire Scientia Vascular for $550 million, enhancing its neurovascular portfolio. The acquisition aims to improve stroke treatment by integrating Scientia's innovative access technologies, making procedures easier and more efficient for physicians. Expected to close in the first half of FY27, the deal positions Medtronic to contribute to better patient outcomes as stroke remains a leading cause of death globally.
Read more →MDTMiniMed announces pricing of initial public offering
MiniMed Group, Inc., a subsidiary of Medtronic, has priced its initial public offering at $20.00 per share, with 28 million shares available. Trading is set to begin on Nasdaq under the symbol 'MMED' on March 6, 2026. Medtronic will maintain a majority stake in MiniMed post-IPO, using proceeds for corporate purposes and debt repayment.
Read more →MDTMiniMed to begin trading on Nasdaq Global Select Market Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that MiniMed Group, Inc. (Nasdaq: MMED) will begin trading today on...
Medtronic plc announced that MiniMed Group, Inc. will begin trading on the Nasdaq Global Select Market under the symbol MMED following its initial public offering. This event marks a significant milestone as the offering was oversubscribed and became the second largest IPO in the Medtech sector. By positioning MiniMed as a standalone entity, Medtronic aims to enhance agility and focus resources on long-term value creation strategies.
Read more →MDTMedtronic announces cash dividend for fourth quarter of fiscal year 2026
Medtronic plc has announced a cash dividend of $0.71 per ordinary share for the fourth quarter of fiscal year 2026. This decision aligns with the company's ongoing commitment to increasing shareholder returns, having raised its dividend for 48 consecutive years. The dividend will be payable on April 17, 2026, to shareholders on record by March 27, 2026.
Read more →MDTMedtronic CFO Thierry Piéton to speak at upcoming investor conferences
Medtronic plc has announced that CFO Thierry Piéton will participate in investor conferences, including the Barclays 28th Annual Global Healthcare Conference and the Leerink Partners Global Healthcare Conference. These events will feature live webcasts, allowing investors to engage with the company's leadership. Medtronic continues to emphasize its commitment to transparency and investor relations.
Read more →MDTMedtronic begins EMEA commercial launch of MiniMed Go Smart MDI system with Simplera sensor
Medtronic has announced the commercial launch of the MiniMed Go Smart MDI system with the Simplera sensor in Europe. This innovative system integrates data from the InPen smart insulin pen and Simplera sensor into a single mobile app, providing real-time insights and alerts for diabetes management. The launch will be rolled out gradually across Europe, aiming to enhance the quality of care for individuals using multiple daily injections.
Read more →MDTMiniMed announces launch of IPO roadshow
MiniMed Group, Inc., a subsidiary of Medtronic, has initiated a roadshow for its IPO, offering 28 million shares priced between $25.00 and $28.00. This move is part of Medtronic's plan to separate its Diabetes business into an independent entity. Medtronic will retain a significant stake post-IPO, and proceeds will be used for corporate purposes and debt repayment.
Read more →MDTMedtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
Medtronic plc reported strong financial results for Q3 FY26, with worldwide revenue reaching $9.017 billion, reflecting an 8.7% increase. The company achieved 6% organic revenue growth, driven by a robust cardiovascular portfolio. CEO Geoff Martha expressed confidence in sustaining long-term growth through innovation and market expansion. Medtronic reiterated its FY26 guidance for organic revenue growth and diluted EPS.
Read more →MDTMedtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters Cardiovascular portfolio up 11% year-over-year Cardiac Ablation Solution
Medtronic reported strong financial results for the third quarter of fiscal year 2026, achieving 8.7% revenue growth and 6.0% organic growth. The company highlighted significant advancements in its Cardiovascular portfolio, particularly an 80% increase in revenue from Cardiac Ablation Solutions. Medtronic's robust innovation pipeline was emphasized, bolstered by recent regulatory approvals for its surgical technologies. Despite the positive growth, the company also noted potential impacts from tariffs and ongoing market risks.
Read more →MDTMedtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its third quarter (Q3) of fiscal year 2026 ...
Medtronic plc reported strong financial results for Q3 of fiscal year 2026, achieving $9.0 billion in revenue, an 8.7% increase compared to the previous year. The company's Cardiac Ablation Solutions segment saw remarkable growth of 80%, driven by its pulsed field ablation portfolio. Medtronic also secured FDA clearances for new surgical systems and reiterated its guidance for organic revenue growth and EPS for the fiscal year.
Read more →MDTMedtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic Medtronic today announced that the first U.S. commercial surgical case using its recently FDA-cleared Hugo™ robotic-assisted surgery (RAS) system has ...
Medtronic announced the successful performance of the first U.S. commercial surgery using its FDA-cleared Hugo robotic-assisted surgery system at Cleveland Clinic. The surgery, a robotic-assisted prostatectomy, was carried out by Dr. Jihad Kaouk, showcasing the system's potential to expand access to minimally invasive surgery. The Hugo RAS system is designed to address challenges in operating room scheduling and infrastructure, offering a flexible surgical option. This marks a significant advancement in surgical robotics in the U.S., with plans for future indications in gynecologic and general surgeries.
Read more →MDTMedtronic receives FDA clearance for Stealth AXiS™ surgical system, first integrated planning, navigation and robotics platform for spine surgery
Medtronic has received FDA clearance for its Stealth AXiS™ surgical system, a groundbreaking platform that integrates planning, navigation, and robotics for spine surgery. This system aims to enhance surgical precision and streamline workflows by providing real-time visibility into spinal motion. It is designed for use in various clinical settings and supports future applications in cranial and ENT procedures.
Read more →MDTMedtronic to announce financial results for its third quarter of fiscal year 2026
Medtronic plc has announced that it will release its financial results for the third quarter of fiscal year 2026 on February 17, 2026. This announcement follows the end of the quarter on January 23, 2026. The company emphasizes its commitment to addressing major health challenges through innovative technologies and therapies.
Read more →MDTMedtronic advances its innovation strategy with intent to acquire CathWorks
Medtronic plc has announced its intent to acquire CathWorks, a medical device company focused on transforming coronary artery disease diagnosis and treatment. The acquisition, valued at up to $585 million, follows a successful partnership and aims to leverage AI technology for improved patient outcomes. The deal is pending regulatory approval and is expected to close by the end of fiscal year 2026.
Read more →MDTMedtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances
Medtronic has announced significant advancements in diabetes management, including Medicare access for the MiniMed™ 780G system with the Instinct sensor and FDA clearance for its use with ultra rapid-acting insulins. These developments aim to enhance flexibility and choice for individuals with type 1 and insulin-requiring type 2 diabetes, ultimately improving their daily management of the condition. The MiniMed™ 780G system is designed to automate insulin delivery, providing more stable glucose control.
Read more →MDTAffera™ momentum continues as Medtronic announces CE Mark in Europe and U.S. IDE first cases for Sphere-360™ PFA catheter to treat paroxysmal atrial fibrillation
Medtronic has announced two significant milestones for its Sphere-360 catheter, receiving CE Mark approval in Europe and completing initial cases in the Horizon 360 IDE pivotal trial in the U.S. This innovative catheter is designed for treating paroxysmal atrial fibrillation and integrates seamlessly with the Affera mapping and ablation system. The Sphere-360's unique design allows for effective treatment without rotation, enhancing patient care.
Read more →MDTMedtronic Diabetes announces FDA clearance for MiniMed Go™ Smart MDI system featuring Instinct sensor made by Abbott
Medtronic has received FDA clearance for its MiniMed Go™ Smart MDI system, which integrates the InPen™ smart insulin pen with Abbott's Instinct sensor. This innovative system aims to simplify diabetes management for individuals on multiple daily injections by providing real-time insights and actionable guidance. The commercial launch is expected in the U.S. this spring.
Read more →MDTMedtronic Diabetes announces FDA clearance for MiniMed Go™ Smart MDI system featuring Instinct sensor made by Abbott Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its...
Medtronic has received FDA 510(k) clearance for its MiniMed Go™ Smart MDI system, which integrates the InPen™ smart insulin pen with Abbott's Instinct sensor. This system provides users with real-time glucose data, missed dose alerts, and actionable guidance, aiming to enhance diabetes management for individuals reliant on multiple daily injections. The commercial launch is expected in the U.S. this spring.
Read more →MDTStudy showed MiniMed™ 780G system achieved ADA-recommended time-in-range goals even on days users forgot to bolus A new real-world retrospective analysis published in Diabetes Care showed that users of the MiniMed™ 780G system achieved American Diabetes...
A recent study published in Diabetes Care found that users of the MiniMed™ 780G insulin system achieved American Diabetes Association-recommended time-in-range goals despite occasionally missing mealtime boluses. The analysis examined real-world data from over 369,000 users and showed that nearly 71.2% of users maintained optimal time-in-range even on missed bolus days when utilizing the system's recommended settings. This highlights the device's capability to adjust insulin delivery automatically, thus enhancing diabetes management.
Read more →MDTMedtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference
Medtronic plc will participate in the 44th annual J.P. Morgan healthcare conference on January 12, 2026. CEO Geoff Martha will present and answer questions, alongside CFO Thierry Piéton. A live webcast will be available for those interested in the presentation and Q&A session. Medtronic continues to lead in healthcare technology with innovative solutions.
Read more →MDTMedtronic announces filing of IPO registration statement for Diabetes business, MiniMed
Medtronic has filed a registration statement for an IPO of its Diabetes business, MiniMed, with the SEC. The IPO aims to raise capital and establish MiniMed as a standalone public company. The offering's details, including share quantity and pricing, are yet to be determined, pending SEC review and market conditions.
Read more →MDTMedtronic announces filing of IPO registration statement for Diabetes business, MiniMed Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Diabetes business, which as previously announced will...
Medtronic plc has filed a registration statement for the initial public offering (IPO) of its Diabetes business, which will be branded MiniMed. The offering is set to take place after SEC review, and the company plans to list its shares on the Nasdaq Global Select Market under the symbol MMED. While the number of shares and pricing details are yet to be disclosed, the IPO represents a strategic move to capitalize on its innovative diabetes technologies and support. Major financial institutions will assist in managing the offering.
Read more →MDTMedtronic announces cash dividend for third quarter of fiscal year 2026
Medtronic plc has declared a cash dividend of $0.71 per ordinary share for the third quarter of fiscal year 2026. This decision aligns with the company's previous announcement of a dividend increase made in May 2025. The dividend is set to be paid on January 16, 2026, to shareholders recorded by December 26, 2025.
Read more →MDTMedtronic announces FDA clearance of Hugo™ robotic-assisted surgery system for urologic surgical procedures
Medtronic has received FDA clearance for its Hugo robotic-assisted surgery system, designed for urologic procedures. This system aims to provide hospitals with more choices in robotic surgery, addressing existing capacity and access challenges. The Hugo RAS system is expected to enhance minimally invasive surgical options and is backed by successful clinical study outcomes.
Read more →MDTMedtronic begins U.S. commercial launch of the MiniMed™ 780G system with the Instinct sensor, made by Abbott
Medtronic has announced the U.S. commercial launch of the MiniMed™ 780G system integrated with Abbott's Instinct sensor. This system, which received FDA clearance earlier this year, automates insulin delivery based on real-time glucose readings. The launch is expected to enhance diabetes management for users, providing a more seamless experience. Positive feedback from early users highlights its effectiveness in improving diabetes care.
Read more →MDTMedtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum
Medtronic reported robust financial results for Q2 FY26, with revenues reaching $8.961 billion, a 6.6% increase. The company highlighted strong growth in its Cardiac Ablation Solutions segment, particularly driven by its pulsed field ablation portfolio. Medtronic raised its revenue and EPS guidance for the fiscal year, reflecting confidence in ongoing business momentum and strategic investments.
Read more →MDTMedtronic reports strong second quarter fiscal 2026 financial results, enterprise growth drivers accelerate momentum Cardiac Ablation Solutions growth of 71% on strength of pulsed field
Medtronic plc announced its strong second quarter financial results for fiscal year 2026, ending October 24, 2025. The company's revenue reached $9.0 billion, marking a 6.6% increase, with notable growth in Cardiac Ablation Solutions at 71%. Medtronic raised its revenue and adjusted earnings per share (EPS) guidance for FY26, driven by a robust performance across its product portfolios and strong market demand. The reported figures underscore the company's operational strength and strategic investments in growth areas.
Read more →MDTMedtronic to announce financial results for its second quarter of fiscal year 2026
Medtronic plc has announced it will report its financial results for the second quarter of fiscal year 2026 on November 18, 2025. This quarter ended on October 24, 2025. Additionally, the company plans to release results for the third and fourth quarters on February 17, 2026, and May 20, 2026, respectively. Further details will be provided closer to the events.
Read more →MDTU.S. Centers for Medicare & Medicaid Services finalizes National Coverage Determination for the Medtronic Symplicity Spyral™ renal denervation (RDN) system
Medtronic announced that the Centers for Medicare & Medicaid Services has finalized a National Coverage Determination for the Symplicity Spyral renal denervation system. This decision allows Medicare patients with uncontrolled hypertension to access this innovative treatment. The procedure is minimally invasive and has demonstrated sustained blood pressure reductions, enhancing patient care options.
Read more →MDTThree-year SPYRAL HTN-ON MED results show sustained, 18 mmHg office-based blood pressure reductions
Medtronic announced long-term results from the SPYRAL HTN-ON MED trial, demonstrating that patients receiving the Symplicity Spyral renal denervation procedure achieved significant reductions in blood pressure over three years. The study highlighted the procedure's durability and safety, with no major complications reported. These findings were presented at the 2025 TCT conference, reinforcing the effectiveness of the treatment for patients with uncontrolled hypertension.
Read more →MDTMedtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions
Medtronic's BrainSense™ Adaptive Deep Brain Stimulation has been named one of TIME's Best Inventions for 2025. This innovative closed-loop system personalizes therapy for Parkinson's patients by adjusting stimulation based on real-time brain activity. With over 1,000 patients already benefiting from this technology, it represents a significant advancement in neuromodulation and brain-computer interface integration.
Read more →MDTMedtronic initiates U.S. IDE clinical study evaluating Hugo™ robotic-assisted surgery system for gynecological procedures
Medtronic has launched the Embrace Gynecology IDE clinical study to assess the safety and effectiveness of its Hugo robotic-assisted surgery system for gynecological procedures. The study will enroll up to 70 patients across five U.S. hospitals, with the first total hysterectomies already completed. This initiative aims to enhance treatment options for women facing gynecological conditions.
Read more →MDTMedtronic Announces Closing of Public Offering of €1.5 Billion of Senior Notes
Medtronic plc has successfully closed a public offering of €1.5 billion in senior notes, consisting of €750 million due in 2030 and another €750 million due in 2045. The net proceeds of approximately €1.49 billion will be used to repay existing senior notes due in 2025. This offering was managed by Deutsche Bank and Goldman Sachs.
Read more →MDTMedtronic secures FDA approval for the Altaviva™ device, a simple experience for treating urge urinary incontinence Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today that it has received U.S. Food and Drug Administration (FDA)...
Medtronic plc has received FDA approval for the Altaviva device, which offers a minimally invasive treatment for urge urinary incontinence. This device, implantable near the ankle, helps restore bladder control through electrical impulses and is designed for patients' ease of use. Aiming to alleviate a common but often unspoken health issue, the Altaviva device is expected to transform the lives of approximately 16 million people in the U.S. who suffer from this condition. The device boasts features such as a 15-year battery lifespan and MRI compatibility, eliminating common barriers associated with bladder control treatments.
Read more →MDTMedtronic Announces Pricing of €1.5 Billion of Senior Notes
Medtronic plc has announced the pricing of €1.5 billion in senior notes, consisting of €750 million of 2.950% notes due in 2030 and €750 million of 4.200% notes due in 2045. The proceeds will be used to repay existing senior notes due in 2025. The offering is expected to close on September 29, 2025.
Read more →MDTMedtronic initiates global pivotal study of cardiac pacing in a new patient population Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the initiation of a pivotal study evaluating the use of elevated ...
Medtronic plc has launched a pivotal study named ELEVATE-HFpEF to evaluate a new approach in cardiac pacing for patients suffering from Heart Failure with Preserved Ejection Fraction (HFpEF). This study will explore the efficacy of personalized pacing rates using conduction system pacing, which could provide a new treatment option for patients who currently have limited treatment possibilities. The study is set to enroll up to 700 participants globally, leveraging data to seek new pacing indications for these patients. This innovative research may significantly impact the quality of life and clinical outcomes for millions affected by HFpEF.
Read more →MDTStudy of Medtronic Hugo™ robotic-assisted surgery system in hernia repair meets safety and effectiveness endpoints Medtronic plc (NYSE: MDT) today announced results from the Enable Hernia Repair clinical study evaluating the performance of the Hugo™...
Medtronic plc has announced positive results from the Enable Hernia Repair clinical study, the first Investigational Device Exemption study for robotic-assisted hernia repair in the U.S. The study demonstrated that the Hugo RAS system successfully met its primary safety and effectiveness endpoints and surpassed expectations. This innovative approach is expected to enhance surgical options for patients requiring hernia repair and is supported by data from a multi-center clinical trial involving 193 patients.
Read more →MDTFDA Clears MiniMed™ 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory...
Medtronic plc has achieved significant FDA milestones with its MiniMed™ 780G system. The system has been approved for integration with Abbott's Instinct sensor, enhancing diabetes management for type 1 diabetes patients. Additionally, the MiniMed™ 780G system is now approved for use in adults with insulin-requiring type 2 diabetes, marking it as the first automated insulin delivery system with Meal Detection™ technology. This expansion is aimed at reducing the treatment burden for patients and improving glycemic control.
Read more →MDTMedtronic executives to speak at upcoming investor conferences Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the following investor conferences: 2025...
Medtronic plc (NYSE: MDT) announced its participation in several upcoming investor conferences in September 2025. Executives including CEO Geoff Martha and CFO Thierry Piéton will answer questions during these events, showcasing the company's commitment to investor relations. The live webcasts will allow investors to access the sessions in real-time, with archived recordings available later. Medtronic continues to emphasize its role as a leader in global healthcare technology.
Read more →MDTMedtronic reports first quarter fiscal 2026 financial results 11 th quarter in a row of mid-single digit organic revenue growth Poised to accelerate growth
Medtronic plc reported its financial results for the first quarter of fiscal year 2026, achieving $8.6 billion in revenue, marking an 8.4% increase year-over-year. This quarter represents the 11th consecutive period of mid-single digit organic revenue growth, driven by strong performances across various product categories, especially Cardiac Ablation Solutions. The company raised its EPS guidance for FY26 in light of its outperformance and positive adjustments in tariff impacts. Medtronic remains optimistic about accelerating growth in the latter half of the fiscal year.
Read more →MDTMedtronic announces Board appointments and shareholder value creation initiatives to advance strategic priorities Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the Medtronic Board of Directors has appointed John Groetelaars...
Medtronic plc has appointed John Groetelaars and Bill Jellison as independent directors to its Board of Directors. In alignment with its strategic priorities, the Board has established new Growth and Operating committees to enhance focus on portfolio management and operational execution. Medtronic plans to hold an Investor Day in 2026, presenting its strategic goals to shareholders. These developments follow productive discussions with Elliott Investment Management, signaling a proactive approach to shareholder value creation.
Read more →MDTMedtronic reports first quarter fiscal 2026 financial results Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its first quarter (Q1) of fiscal year 2026 ...
Medtronic plc reported its financial results for Q1 FY26, demonstrating an 8.4% increase in worldwide revenue, largely attributed to mid-single digit organic revenue growth for 11 straight quarters. The company highlighted strong performance in several innovative product categories such as Pulsed Field Ablation and Neuromodulation. Medtronic also raised its FY26 EPS guidance, citing improved forecasts regarding tariffs and a commitment to enhancing manufacturing efficiencies and R&D investments. Overall, the company remains optimistic about accelerating revenue growth in the latter half of the fiscal year.
Read more →MDTMedtronic announces cash dividend for second quarter of fiscal year 2026 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 14, 2025, approved the company's cash dividend for the second quarter of...
On August 14, 2025, Medtronic plc's board approved a cash dividend of $0.71 per share for the second quarter of fiscal year 2026. This decision aligns with a previous dividend increase announcement made in May 2025. The dividend will be payable on October 17, 2025, to shareholders on record as of September 26, 2025. Medtronic is recognized as a member of the S&P 500 Dividend Aristocrats index due to its long history of dividend payments.
Read more →MDTMedtronic to announce financial results for its first quarter of fiscal year 2026 Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results on Tuesday, August 19,...
Medtronic plc has announced that it will release its financial results for the first quarter of fiscal year 2026 on August 19, 2025. This announcement follows the end of the quarter on July 25, 2025, and outlines plans to report results for the subsequent quarters in November 2025, February 2026, and May 2026. The company emphasizes its mission to tackle challenging health issues through innovative technologies and solutions, showcasing its commitment to healthcare improvement.
Read more →MDTMedtronic secures CE Mark for MiniMed™ 780G System for insulin-requiring people with diabetes including expanded indications in children as young as two, during pregnancy, and for type 2 diabetes Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of...
Medtronic has obtained CE Mark approval for the expanded indications of its MiniMed™ 780G system, targeting individuals aged two and older with type 1 diabetes, those during pregnancy, and people with type 2 diabetes. This development is backed by clinical data demonstrating improved glucose management and overall quality of life for users. The approval aligns with Medtronic's commitment to enhancing automated insulin delivery technology and addresses significant healthcare needs across diverse populations. The MiniMed™ 780G system is now positioned to revolutionize diabetes care, particularly for younger and expectant patients.
Read more →MDTMedtronic announces appointment of MiniMed chief financial officer ahead of intended separation into standalone company Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) ...
Medtronic plc has appointed Chad Spooner as the chief financial officer of MiniMed, ahead of its planned separation into an independent public company. Spooner, with extensive financial leadership experience, is expected to play a key role in overseeing the finance function for Medtronic Diabetes. The anticipated separation is set to occur within 18 months but is subject to various legal and market conditions. Medtronic aims for MiniMed to uphold its mission of innovative diabetes care as it transitions to independence.
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Dr. Joon Lee as a new director
Medtronic plc has announced the appointment of Dr. Joon Lee as an independent director on its Board of Directors, effective June 18, 2025. Dr. Lee, currently the CEO of Emory Healthcare, Inc., brings over 25 years of leadership experience in healthcare. He will serve on the Science and Technology Committee and the Compensation and Talent Committee, contributing his expertise in clinical research and technology to advance Medtronic's mission of improving patient care.
Read more →MDTMedtronic Board appoints Dr. Joon Lee as a new director Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory ...
Medtronic plc has appointed Dr. Joon Lee, CEO of Emory Healthcare, as an independent director on its Board of Directors, effective June 18, 2025. Dr. Lee will contribute to the Science and Technology and Compensation and Talent Committees. He possesses over 25 years of experience in various leadership roles in healthcare and academic settings, emphasizing his commitment to enhancing patient and provider experiences through data and technology. His expertise is anticipated to support Medtronic's mission of improving health outcomes for patients globally.
Read more →MDTStudies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system Medtronic, a global leader in healthcare technology, will present data at the American Diabetes Association (ADA) 85th Scientific Sessions in...
Medtronic is set to present promising results at the American Diabetes Association's Scientific Sessions regarding their MiniMed™ 780G system. Data indicates significant improvements in glycemic management for patients with insulin-intensive type 2 diabetes, achieving a notable increase in Time in Range and HbA1C reduction. Additionally, the LENNY trial results suggest that young children with type 1 diabetes benefit from better glycemic outcomes and improved sleep quality when using the system in auto mode. Medtronic aims to seek regulatory approval for expanding the device's indications for broader patient use.
Read more →MDTMedtronic announces MiniMed as name for planned New Diabetes Company Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced MiniMed as the name for the planned New Diabetes Company...
Medtronic plc has announced that the planned New Diabetes Company will be named MiniMed, reflecting the company's historical roots in diabetes care. The name honors the legacy of MiniMed's founder and aims to symbolize the company's ongoing commitment to transforming diabetes management. With a focus on innovation, Medtronic seeks to improve patients' quality of life and make diabetes management more predictable. The company anticipates completing the separation within 18 months, pending necessary legal processes.
Read more →MDTMedtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions...
Medtronic plc announced that its chairman and CEO, Geoff Martha, will present at Bernstein's 41st Strategic Decisions Conference on May 29, 2025. Following his presentation, he will participate in a Q&A session alongside Thierry Piéton, the company’s executive vice president and CFO. The presentation aims to address various business strategies and insights relevant to stakeholders. A live webcast will be available for those interested in attending the event virtually.
Read more →MDTMedtronic reports strong finish to its fiscal year with its fourth quarter financial results announces dividend increase Building momentum in key franchises including Pulsed Field Ablat
Medtronic has reported robust financial results for its fourth quarter and fiscal year 2025, with a revenue increase of 3.9% in Q4 and 3.6% for the entire year. The company also achieved significant earnings growth, highlighted by a 67% increase in diluted EPS for Q4. Notably, Medtronic announced a dividend increase, marking its 48th consecutive year of such rises. Strong performance in key product sectors, including Pulsed Field Ablation, indicates positive momentum going forward.
Read more →MDTMedtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year...
Medtronic plc (NYSE: MDT) announced strong financial results for its fourth quarter and fiscal year 2025, with worldwide revenue growth driven by key franchises. The company reported a 3.9% increase in Q4 revenue, alongside a 3.6% rise for FY25, and approved a dividend increase that reflects a consistent growth trend over nearly five decades. Amid positive outlooks, Medtronic plans to separate its Diabetes business into a standalone public company, which could bring operational challenges. The company also expects organic revenue growth of around 5% for fiscal year 2026 despite potential tariff impacts.
Read more →MDTMedtronic announces intent to separate Diabetes business Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its intent to separate its Diabetes business into a new...
Medtronic announced its intent to separate its Diabetes business into an independent company, expected to conclude within 18 months. This strategic move is anticipated to enhance Medtronic's focus on high-margin growth areas and to unlock value for shareholders. The new Diabetes Company will have a strong emphasis on innovation in insulin management and is positioned for long-term success. The separation is projected to improve Medtronic's margins and earnings, as well as maintain its dividend policy.
Read more →MDTMedtronic to announce financial results for its fourth quarter and full fiscal year 2025 Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and ...
Medtronic plc (NYSE: MDT) has announced that it will report its financial results for the fourth quarter and full fiscal year 2025 on May 21, 2025. A news release will be issued in the morning, followed by a video webcast to discuss the results. The company is also planning to disclose its financial results for fiscal year 2026 throughout the year on specified dates. Medtronic emphasizes its commitment to addressing challenging health problems globally through innovative technologies.
Read more →MDTNew survey: 1 in 3 women have not talked to their doctor about heart health, the #1 killer of women A new Medtronic-sponsored survey of women ages 30-50 reveals a significant gap in awareness and discussion around heart health among women and their...
A recent Medtronic-sponsored survey highlights a critical gap in women's discussions about heart health, despite it being the leading killer of women in the U.S. The survey found that many women are more comfortable discussing other sensitive topics than their family health history regarding heart disease. The 'Letter to My Mother' campaign encourages women to engage in conversations about cardiovascular health with maternal figures, aiming to raise awareness and promote preventive measures. Medtronic affirms its ongoing commitment to tailored healthcare solutions for women, particularly in addressing heart disease and related concerns.
Read more →MDTMedtronic Affera™ pulsed field ablation technologies continue to demonstrate promising evidence for atrial fibrillation patients Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical outcomes from two studies in atrial...
Medtronic plc announced positive clinical outcomes from studies on its Affera pulsed field ablation technologies for treating atrial fibrillation (AFib) patients. The Sphere-360 catheter demonstrated an 88% freedom from arrhythmia recurrence at one year and 98% pulmonary vein isolation success. Notably, there were no serious adverse events reported associated with the Sphere-360. Medtronic plans to initiate a U.S. pivotal trial for this technology later this year, continuing its commitment to innovation in cardiac care.
Read more →MDTMedtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption (IDE) clinical...
Medtronic has announced that its Expand URO clinical study successfully met primary safety and effectiveness endpoints for the Hugo robotic-assisted surgery system. This study, which is the largest of its kind in the U.S., demonstrates positive outcomes for robotic-assisted urologic surgery. The results, presented at the American Urologic Association annual meeting, could shift practice standards in urology. Additionally, Medtronic is submitting the Hugo system for U.S. FDA approval, positioning itself to enter a major market for robotic surgery.
Read more →MDTMedtronic receives FDA approval for smallest-diameter, lumenless defibrillation lead, the OmniaSecure™ lead and announces investigational clinical study results Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure™...
Medtronic has received FDA approval for the OmniaSecure defibrillation lead, touted as the world's smallest lead at 4.7 French. This device enables precise delivery and placement within the right ventricle and is indicated for treatment of critical heart conditions. Additionally, investigational results from the LEADR LBBAP study show a 100% defibrillation success rate when the lead is implanted in the left bundle branch area. The product aims to reduce complications associated with larger leads while providing a reliable solution for patients, especially those with smaller anatomies.
Read more →MDTMedtronic advances Abbott CGM partnership with FDA submission of interoperable insulin pump Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has submitted 510(k) applications to the U.S. Food and Drug...
Medtronic plc has submitted 510(k) applications to the FDA for an interoperable insulin pump, which is set to work with Abbott's advanced continuous glucose monitoring system. This initiative aims to enhance diabetes management by providing customers with more integrated options. The partnership signifies a substantial step forward in innovative diabetes care solutions, although the final FDA clearance is still pending. Details on the product will be shared once approval is obtained.
Read more →MDTNew Simplera Sync™ sensor for the MiniMed™ 780G System now FDA approved Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for the...
Medtronic plc has received FDA approval for its Simplera Sync™ sensor, designed for use with the MiniMed™ 780G insulin delivery system. This approval allows for greater flexibility and convenience for diabetes management, utilizing Meal Detection™ technology to optimize insulin delivery. The Simplera Sync™ sensor features an all-in-one design with a two-step insertion process, reducing the need for fingersticks. A limited launch is planned for the fall of 2025, with the sensor joining the existing Guardian™ 4 sensor in the MiniMed™ 780G system.
Read more →MDTMedtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes from the Evolut Low...
Medtronic plc announced promising five-year outcomes from the Evolut Low Risk Trial, highlighting the success of the Evolut TAVR system in low-risk aortic stenosis patients. The data indicates that TAVR offers a lower rate of all-cause mortality or disabling stroke compared to traditional surgery. With 1,414 patients enrolled in the study, the findings reveal that TAVR is a safe and effective alternative for treating severe aortic stenosis. This late-breaking data was presented at the American College of Cardiology Conference and published in the JACC journal.
Read more →MDTSMART Trial two-year data continues to demonstrate superior valve performance for Evolut TAVR™ system in small annulus patients Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or...
Medtronic plc announced two-year results from the SMART Trial, demonstrating that the Evolut TAVR system outperforms the SAPIEN TAVR in patients with a small aortic annulus. The trial, the largest of its kind focused on women, showed comparable outcomes in mortality, disabling stroke, and heart failure hospitalization, while revealing significantly less bioprosthetic valve dysfunction for Evolut. Additional follow-ups are planned over the next five years to assess long-term outcomes, reinforcing the potential advantages of Evolut's differentiated valve design.
Read more →MDTMedtronic announces cash dividend for fourth quarter of fiscal year 2025 The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 6, 2025, approved the company's cash dividend for the fourth quarter of fiscal ...
Medtronic plc has announced a cash dividend of $0.70 per ordinary share for the fourth quarter of fiscal year 2025, following a previously announced dividend increase in May 2024. The dividend will be paid on April 11, 2025, to shareholders recorded by March 28, 2025. This continuance underlines Medtronic's status as a consistent performer in the S&P 500 Dividend Aristocrats index, having increased its annual payments for 47 consecutive years.
Read more →MDTMedtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system for people with Parkinson's For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare...
Medtronic has received FDA approval for its BrainSense™ Adaptive deep brain stimulation system, the first of its kind for Parkinson's disease. This system personalizes therapy based on individual brain activity in real time, enhancing treatment effectiveness. The BrainSense™ Electrode Identifier was also approved, allowing for faster and more precise programming. The launch represents the largest commercial introduction of brain-computer interface technology, seeking to transform care for over one million diagnosed Parkinson's patients in the U.S.
Read more →MDT▼ -7.3%on this news
Medtronic reports third quarter fiscal 2025 financial results Medtronic plc (NYSE: MDT) today announced financial results for its third quarter (Q3) of fiscal year 2025 (FY25), which ended January 24, 2025. Key...
Medtronic plc announced its financial results for the third quarter of fiscal year 2025, revealing a worldwide revenue of $8.292 billion. The company experienced a 2.5% increase in revenue, driven by growth across its Cardiovascular and Neuroscience portfolios. Despite a slight decline in the Medical Surgical Portfolio, Medtronic affirmed its FY25 revenue and earnings guidance, projecting organic revenue growth of 4.75% to 5%. Additionally, their non-GAAP diluted earnings per share were reported at $1.39, representing a 7% increase.
Read more →MDT▼ -7.3%on this news
Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2025 financial results Delivering dur
Medtronic plc has announced its financial results for the third quarter of fiscal year 2025, reporting a revenue increase of 2.5% to $8.292 billion. The company highlighted the growth of its Pulsed Field Ablation products and reaffirmed its full-year revenue and EPS guidance, projecting organic revenue growth of 4.75% to 5%. While the Cardiovascular and Neuroscience portfolios experienced notable growth, the Medical Surgical Portfolio faced challenges, indicating mixed results overall. The company remains optimistic about its earnings power and market position.
Read more →MDTMedtronic to announce financial results for its third quarter of fiscal year 2025 Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of...
Medtronic plc (NYSE: MDT) has announced its schedule to report financial results for the third quarter of fiscal year 2025 on February 18, 2025. A news release will provide summary financial information from the quarter ended on January 24, 2025, followed by a video webcast at 7:00 a.m. CST. Medtronic is also planning to report its fourth-quarter results on May 21, 2025, and the fiscal year 2026 reporting schedule has been outlined. The company emphasizes its commitment to address significant health challenges and communicate effectively with its stakeholders.
Read more →MDTMedtronic appoints Thierry Piéton as Chief Financial Officer Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Thierry Piéton has been appointed Chief Financial Officer...
Medtronic plc has appointed Thierry Piéton as Chief Financial Officer, effective March 3, 2025. Piéton, who joins from Renault Group where he excelled as CFO, will lead Medtronic's global finance organization. Gary Corona, the interim CFO, will transition to Senior Vice President of Corporate Finance. Medtronic's CEO, Geoff Martha, highlighted Piéton's strategic financial leadership and experience in achieving significant shareholder value.
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic appoints Thierry Pi ton as Chief Financial Officer GALWAY
Medtronic plc has announced the appointment of Thierry Pi ton as their new Chief Financial Officer, effective March 3, 2025. Pi ton, who previously served as CFO of Renault Group, brings extensive experience in finance and operational leadership from various industries. The move follows the tenure of Gary Corona as interim CFO, who will transition to a new role while supporting the leadership change. CEO Geoff Martha expressed confidence in Pi ton's capabilities to drive financial strategies that align with company objectives.
Read more →MDTMedtronic achieves CE Mark approval for BrainSense™ Adaptive deep brain stimulation and Electrode Identifier, a groundbreaking advance in personalized, sensing-enabled care for people with Parkinson's through innovative brain-computer interface technology Medtronic plc (NYSE:MDT), a global leader in healthcare technology, announced today CE (Conformité Européenne) Mark approval in the European Union...
Medtronic has achieved CE Mark approval for its BrainSense™ Adaptive deep brain stimulation (aDBS) system and Electrode Identifier in the EU and UK. This approval introduces the world's only closed-loop DBS system that adapts stimulation in real-time based on individual brain activity, presenting a significant advancement in personalized therapy for Parkinson's disease. The official programming of the system has been completed by a neurology expert, marking a milestone in DBS therapy. The technology promises to improve outcomes for patients while enhancing the efficiency of programming for clinicians.
Read more →MDTMedtronic announces CMS national coverage analysis for Symplicity™ Spyral Renal Denervation System Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) is...
Medtronic plc has announced that the Centers for Medicare & Medicaid Services (CMS) is initiating a national coverage analysis for renal denervation procedures using the Symplicity Spyral system. This decision aims to review and develop a Medicare coverage policy for the treatment of hypertension. The analysis process was prompted by Medtronic's request to ensure that Medicare beneficiaries have access to this FDA-approved breakthrough device, with the expected completion date set for October 11, 2025.
Read more →MDTMedtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual J.P. Morgan healthcare...
Medtronic plc is set to participate in the 43rd annual J.P. Morgan healthcare conference on January 13, 2025. Chairman and CEO Geoff Martha will deliver a presentation and engage in a Q&A session with other company leaders. The event will be available via a live webcast for the public to access, alongside an archived session later in the day. This participation highlights Medtronic's commitment to innovation in healthcare technology.
Read more →MDTMedtronic announces cash dividend for third quarter of fiscal year 2025 The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of...
Medtronic plc has declared a cash dividend of $0.70 per share for the third quarter of fiscal year 2025. This decision follows the company's previous announcement of a dividend increase in May 2024. The dividend, consistent with Medtronic's commitment to shareholder returns, will be payable on January 10, 2025, to shareholders of record by December 27, 2024. Medtronic has a strong track record of increasing its annual dividend for 47 consecutive years, highlighting its financial stability and commitment to returning value to investors.
Read more →MDTMedtronic receives FDA clearance for new InPen™ app, paving the way for its Smart MDI system launch with Simplera™ CGM Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) clearance for its new...
Medtronic plc has received FDA clearance for its new InPen™ app, which will work in conjunction with the company's Smart MDI system and Simplera™ continuous glucose monitor (CGM). This new system is unique in its ability to provide real-time recommendations for insulin dosing, particularly for missed or incorrect doses, aiming to improve diabetes management for users on multiple daily injections. Medtronic plans to begin a limited market release, followed by a broader commercial launch.
Read more →MDTMedtronic reports second quarter fiscal 2025 financial results Medtronic plc (NYSE: MDT) today announced financial results for its second quarter (Q2) of fiscal year 2025 (FY25), which ended October 25, 2024. Key ...
Medtronic plc released its financial results for the second quarter of fiscal year 2025, revealing a 5.3% increase in worldwide revenue, totaling $8.403 billion. Notable gains were seen in net income and diluted earnings per share, which rose by 40% and 46% respectively. The company raised its guidance for fiscal year 2025, projecting organic revenue growth between 4.75% and 5%. The strong performance was attributed to innovations across multiple product franchises, including cardiovascular devices and diabetes management products.
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2025 financial results Delivering on
Medtronic plc announced its second quarter fiscal 2025 financial results, reporting a revenue increase of 5.3% to $8.4 billion. The company raised its revenue growth and earnings per share guidance for the fiscal year, reflecting strong performance in several portfolios, including cardiovascular and neurosciences. Innovations and successful product launches have significantly contributed to this growth. Additionally, the company achieved notable reductions in environmental impact ahead of schedule, showcasing its commitment to sustainability.
Read more →MDTMedtronic to announce financial results for its second quarter of fiscal year 2025 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of...
Medtronic plc has announced that it will report its financial results for the second quarter of fiscal year 2025 on November 19, 2024. The report will cover the financial period ending on October 25, 2024, and will be followed by a video webcast to discuss these results. A preview of future quarterly results is also provided, indicating Medtronic's commitment to regular financial transparency. The announcement continues to highlight the company's status as a key player in the healthcare technology sector.
Read more →MDTCMS grants Transitional Pass-Through Payment for Medtronic Symplicity Spyral™ renal denervation catheter Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the Centers for Medicare & Medicaid Services (CMS) has...
Medtronic has announced a significant milestone with the Centers for Medicare & Medicaid Services granting transitional pass-through payment for its Symplicity Spyral renal denervation catheter, effective January 1, 2025. This move aims to improve patient access to innovative hypertension treatments by alleviating financial barriers for hospitals. The Symplicity procedure, which uses radiofrequency energy to target nerves contributing to high blood pressure, has gained approval from the FDA and is currently available in over 75 countries. Medtronic's continued collaboration with CMS seeks to expand coverage and access for patients with uncontrolled hypertension.
Read more →MDTSPYRAL HTN-ON MED study shows significant, consistent, long-term blood pressure lowering effect at two years Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new, long-term data from its SPYRAL HTN-ON MED clinical trial...
Medtronic plc announced promising long-term results from its SPYRAL HTN-ON MED clinical trial, showing significant reductions in blood pressure for patients treated with the Symplicity Spyral renal denervation system over two years. The study indicates the safety and sustained effectiveness of this treatment for uncontrolled hypertension. Medtronic also revealed plans to expand the GSR-DEFINE clinical trial to the U.S. and investigate multi-organ denervation for enhanced blood pressure management, underscoring their commitment to advancing clinical data in hypertension treatment.
Read more →MDTA new paradigm in electrophysiology: Medtronic receives FDA approval of Affera™ Mapping and Ablation System and Sphere-9™ Catheter Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug Administration (FDA) approval of the ...
Medtronic has announced the FDA approval of its Affera Mapping and Ablation System along with the Sphere-9 Catheter, making it the first company to offer two pulsed field ablation technologies for treating persistent atrial fibrillation (Afib) and atrial flutter. This novel system integrates both mapping and ablation technologies, promoting increased workflow efficiency and improved outcomes for patients. The approval follows promising results from the pivotal SPHERE Per-AF study. Medtronic's innovative approach aims to address the challenges faced by healthcare providers in treating heart rhythm disorders.
Read more →MDTVoluntary recall notifying Medtronic insulin pump users of potential risks of shortened pump battery life Medtronic plc (NYSE: MDT), a global leader in healthcare technology, voluntarily issued a field action starting on July 31, 2024, notifying global...
Medtronic has voluntarily issued a recall affecting its MiniMed 600 and 700 series insulin pumps due to reports of shortened battery life. The recall, classified as class I by the FDA, stems from concerns that physical impacts on the device may lead to premature battery failure, resulting in potential health risks such as hyperglycemia and diabetic ketoacidosis. Medtronic advises users to monitor built-in alerts for battery status and contact the company for pump replacement if necessary. The company has recorded significant health-related incidents in users that may be connected to these issues.
Read more →MDTNew clinical data demonstrate excellent lesion durability with PulseSelect™ Pulsed Field Ablation System in real-world setting as approvals and adoption expand globally Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the presentation of clinical study results demonstrating a high...
Medtronic plc has announced positive clinical study results for its PulseSelect Pulsed Field Ablation System, which demonstrated a 98% durability rate of lesion formation in treating atrial fibrillation. This study, presented at the Asia Pacific Heart Rhythm Society meeting, highlights the system's effectiveness in achieving pulmonary vein isolation in a real-world setting. The announcement coincides with the global expansion of PulseSelect, with significant market approvals in Asia, including Japan. Medtronic emphasizes the importance of these results in enhancing the treatment landscape for atrial fibrillation worldwide.
Read more →MDTMedtronic expands AiBLE™ spine surgery ecosystem with new technologies and Siemens Healthineers partnership Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced today at the North American Spine Society (NASS) 39th Annual Meeting...
Medtronic plc has launched several new software, hardware, and imaging technologies at the North American Spine Society Annual Meeting aimed at enhancing the AiBLE™ ecosystem for spine surgeries. In addition, Medtronic announced a strategic partnership with Siemens Healthineers, focusing on advanced pre- and post-operative imaging technologies to improve patient care in spinal conditions. The collaboration includes the integration of the Siemens Multitom Rax™ imaging system into the AiBLE™ platform, which is expected to enhance clinical outcomes through improved imaging and navigation technology.
Read more →MDTMedtronic chairman and CEO Geoff Martha to speak at the Wells Fargo Healthcare Conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 2024 Wells Fargo Healthcare Conference ...
Medtronic plc (NYSE: MDT) has announced its participation in the 2024 Wells Fargo Healthcare Conference, scheduled for September 4, 2024. Geoff Martha, the chairman and CEO, will be speaking about the medtech industry during the event. A live webcast of the discussion will be accessible, with an archive available later in the day. Medtronic is recognized for its leadership in healthcare technology and innovative solutions for various health conditions.
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2025 financial results Product innova
Medtronic plc announced its financial results for the first quarter of fiscal year 2025, reporting revenues of $7.9 billion and strong growth across key divisions. The company raised its guidance for organic revenue growth and diluted non-GAAP EPS, signaling confidence in its ongoing product innovation and market performance. Notably, the Cardiovascular and Neuroscience portfolios experienced significant growth, although the Medical Surgical division faced slight revenue declines. Overall, the company remains focused on delivering innovative solutions in healthcare technology.
Read more →MDTMedtronic reports first quarter fiscal 2025 financial results Medtronic plc (NYSE: MDT) today announced financial results for its first quarter (Q1) of fiscal year 2025 (FY25), which ended July 26, 2024. Key...
Medtronic plc has announced its financial results for the first quarter of fiscal year 2025, ending July 26, 2024, showcasing a revenue of $7.915 billion. The company exceeded expectations with a 2.8% increase in overall revenue and a notable rise in adjusted EPS, prompting a raise in guidance for the fiscal year. Key segments, including Cardiovascular and Diabetes, saw robust organic revenue growth, signaling strong market performance and continued investment in product innovation.
Read more →MDTMedtronic announces cash dividend for second quarter of fiscal year 2025 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of...
Medtronic plc's board of directors approved a cash dividend of $0.70 per ordinary share for the second quarter of fiscal year 2025, consistent with a prior increase disclosed in May 2024. This dividend will be payable on October 11, 2024, to shareholders of record before September 27, 2024. Medtronic is recognized as a Dividend Aristocrat, having increased its dividend payments for 47 consecutive years.
Read more →MDTMedtronic to announce financial results for its first quarter of fiscal year 2025 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of...
Medtronic plc (NYSE: MDT) announced it will release financial results for its first quarter of fiscal year 2025 on August 20, 2024. The results will include a summary of financial information and will be followed by a video webcast discussing these results. Medtronic has also scheduled its financial results announcements for the remaining quarters of fiscal year 2025. The company emphasizes its commitment to innovative healthcare solutions and impactful technologies.
Read more →MDTMedtronic announces FDA approval of Simplera™ CGM and global partnership with Abbott Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for its...
Medtronic plc has received FDA approval for its Simplera™ continuous glucose monitor (CGM), the company's first disposable device designed to enhance the user experience in diabetes management. The new CGM, which is significantly smaller and easier to use than previous models, will be released in a limited market rollout. Additionally, Medtronic has announced a global partnership with Abbott to develop an integrated CGM solution that will complement its health technology offerings. This collaboration is expected to enhance the capabilities and accessibility of diabetes management systems.
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic announces departure of Karen Parkhill, Chief Financial Of
Medtronic plc announced the resignation of its Chief Financial Officer, Karen Parkhill, who will be joining HP Inc. after serving for eight years. CEO Geoff Martha expressed gratitude for her leadership throughout challenging times, notably the pandemic. Parkhill will remain in her role until August 2, after which Gary Corona will step in as interim CFO while the company seeks a permanent successor. Medtronic also reaffirmed its financial guidance for the first quarter and the full fiscal year 2025.
Read more →MDTMedtronic announces departure of Karen Parkhill, Chief Financial Officer Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Karen Parkhill will resign as executive vice president and...
Medtronic plc has announced the resignation of Karen Parkhill as Chief Financial Officer to take a position at HP Inc., effective August 2. Parkhill has been with Medtronic for eight years, contributing significantly to the company's operations, especially during the pandemic. Medtronic's CEO Geoff Martha and Parkhill both expressed gratitude for her leadership and emphasized the company's commitment to its growth strategy. Following her departure, Gary Corona will serve as the interim CFO while the company seeks a successor.
Read more →MDTNew MiniMed™ 780G system data demonstrates ability to address persistent blood sugar challenges for people with type 1 diabetes Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a comprehensive body of new data at the American Diabetes...
Medtronic plc is showcasing new data on the MiniMed™ 780G system at the American Diabetes Association's 84th Scientific Sessions, illustrating its effectiveness in mitigating persistent blood sugar challenges for individuals with type 1 diabetes. The comprehensive results indicate that the system significantly reduces morning hyperglycemia, known as the dawn phenomenon, and enhances overnight sleep quality for users. Additionally, the upcoming iteration of the MiniMed™ 780G system paired with the Simplera Sync™ sensor promises to further alleviate diabetes management burdens, although this sensor remains investigational in the U.S. market.
Read more →MDTMedtronic chairman and CEO Geoff Martha to speak at Goldman Sachs global healthcare conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 45th annual Goldman Sachs global...
Medtronic plc has announced that its chairman and CEO Geoff Martha will speak at the 45th annual Goldman Sachs global healthcare conference on June 11, 2024, at 10:40 a.m. EDT. The Q&A session will be accessible via a live webcast, with an archived version available later that day. This event reflects Medtronic's ongoing commitment to engage with the investor community and share insights on the company's healthcare innovations and challenges.
Read more →MDTMedtronic announces closing of public offering of €3.0 billion of senior notes Medtronic plc (the Company ) (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has closed a registered public...
Medtronic plc announced the closure of a public offering totaling €3.0 billion in senior notes. The notes include multiple tranches with varying due dates and interest rates. The net proceeds, approximately €2.97 billion, are expected to support general corporate needs, including debt repayment. This positioning aims to enhance the company's financial flexibility and stability going forward.
Read more →MDTMedtronic announces pricing of €3.0 billion of senior notes Medtronic plc (the Company ) (NYSE: MDT) announced today that its wholly-owned indirect subsidiary, Medtronic, Inc., has priced an offering (the...
Medtronic plc has announced the pricing of an offering totaling €3.0 billion in senior notes with varying maturities. These notes include €850 million due in 2029, €850 million due in 2036, €600 million due in 2043, and €700 million due in 2053. The proceeds are expected to support general corporate purposes, including repayment of existing debt. The offering is set to close on June 3, 2024, pending customary closing conditions.
Read more →MDT▼ -5.1%on this newsshared move
Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2024 financial results
Medtronic plc reported its fiscal year 2024 financial results, indicating a revenue increase of 3.6% to $32.4 billion. Despite a 45% decrease in Q4 net income, the company experienced broad revenue growth across its segments. Medtronic announced a dividend increase for the 47th consecutive year and received FDA and NMPA approvals for several products. The company expressed optimism about new product cycles and ongoing momentum heading into fiscal year 2025.
Read more →MDT▼ -5.1%on this newsshared move
Medtronic reports full year and fourth quarter fiscal 2024 financial results; announces dividend increase Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter (Q4) and fiscal year 2024 (FY24), which ended April 26, 2024. Key...
Medtronic plc (NYSE: MDT) reported its fourth quarter and fiscal year 2024 financial results, showcasing 0.5% revenue growth for Q4 and a total of $32.364 billion for FY24. The company achieved broad growth across its segments, including notable increases in its Diabetes product line. However, net income showed a decline of 45% in Q4. Medtronic also announced a dividend increase, marking 47 consecutive years of dividend growth, while providing optimistic guidance for FY25 organic revenue growth between 4% and 5%.
Read more →MDTMiniMed™ 780G system recognized among Fast Company's 2024 World Changing Ideas Fast Company announced that the Medtronic MiniMed™ 780G automated insulin delivery system has been recognized in the Best World-Changing Idea, North...
Medtronic's MiniMed™ 780G automated insulin delivery system has been honored in Fast Company's 2024 World Changing Ideas Awards for the North America category. This recognition underscores Medtronic's ongoing commitment to revolutionizing diabetes care through technological innovation. The MiniMed™ 780G system, which includes Meal Detection™ technology, aims to alleviate the challenges faced by individuals managing diabetes. This acknowledgment highlights the importance of dedicated efforts toward improving patient outcomes in diabetes management.
Read more →MDTMedtronic Affera™ Mapping and Ablation System with Sphere-9™ Catheter achieves endpoints for safety and efficacy, providing promising evidence for the future of atrial fibrillation treatment Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive results demonstrating excellent safety and efficacy of...
Medtronic has announced positive results from the SPHERE Per-AF trial, showcasing the effectiveness and safety of its Affera Mapping and Ablation System with Sphere-9 Catheter for treating persistent atrial fibrillation. The trial compared this innovative catheter to a conventional radiofrequency ablation catheter, revealing impressive outcomes in terms of efficiency and quality of life for patients. The company has filed for FDA approval for this investigational device in the U.S., with prior CE Mark approval received in March 2023. This advancement may change treatment practices in the electrophysiology field.
Read more →MDTLate-breaking data show reliable performance of small-diameter defibrillation lead, the Medtronic OmniaSecure™ Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that its investigational OmniaSecure™ defibrillation lead met its...
Medtronic announced that its investigational OmniaSecure defibrillation lead has successfully met its primary safety and effectiveness endpoints in the global LEADR Pivotal Trial. The results, presented at Heart Rhythm 2024, showed a 97.5% success rate in defibrillation testing among 119 patients. The study also reported a 97.1% freedom from lead-related major complications at six months. The lead, being the smallest transvenous defibrillation model available, aims to enhance the reliability and effectiveness of life-saving therapies for patients at risk of sudden cardiac death.
Read more →MDTMedtronic to announce financial results for its fourth quarter and full fiscal year 2024 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and...
Medtronic plc, a leader in healthcare technology, will announce its financial results for the fourth quarter and full fiscal year 2024 on May 23, 2024. A news release will detail financial summaries, and a video webcast will follow to discuss these results. Medtronic also outlined the dates for reporting results for fiscal year 2025, showing its commitment to transparency and communication with stakeholders. The company continues to address significant health challenges through its innovative technologies.
Read more →MDTMedtronic receives FDA approval for Inceptiv™ closed-loop spinal cord stimulator Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the ...
Medtronic has received FDA approval for its Inceptiv™ closed-loop spinal cord stimulator designed to treat chronic pain. This innovative device features a closed-loop system that adjusts stimulation in real time based on biological signals, enhancing therapy efficacy. Notably, it is the first of its kind to offer unrestricted MRI access and boasts the smallest size among implantable SCS devices. Medtronic plans to launch the Inceptiv system in the U.S. shortly after its approval in Europe and Japan.
Read more →MDTAmericans favor quality over quantity in pursuit of longevity Americans overwhelmingly say that when they think about longevity, it's more than just living longer—it's about living their healthiest, best lives....
A recent survey by Medtronic and Morning Consult reveals that a majority of Americans prefer a shorter, healthier life versus a longer one with health issues. While many aspire to live to age 90, approximately 66% would choose quality over quantity when it comes to longevity. The survey also highlights a disconnect, as only a minority are taking proactive health measures and utilizing available healthcare technology. Despite this, there is confidence that innovations in healthcare can significantly enhance both lifespan and quality of life.
Read more →MDTMedtronic unveils the future of AI in GI: Genius Summit 2024 reveals innovations and collaborations that advance endoscopic care Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic ...
Medtronic plc has introduced significant advancements in artificial intelligence for endoscopic care during the Genius Summit 2024. The company launched ColonPRO™, an upgraded software for its GI Genius™ system, which improves polyp detection, featuring enhanced algorithms and a reduction in false positives. Additionally, Medtronic announced a collaboration with Modernizing Medicine to integrate real-time AI-generated data from the GI Genius™ system into their gGastro® electronic health records software. These initiatives aim to streamline physician workflows, enhance patient care, and further Medtronic's commitment to colorectal cancer care.
Read more →MDTThe Medtronic Sphere-360™ Pulse Field Ablation (PFA) catheter, a new paradigm in single-shot ablation, demonstrates impressive results in treating paroxysmal atrial fibrillation Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for...
Medtronic plc has announced positive clinical trial results for its Sphere-360 Pulse Field Ablation catheter, which treats paroxysmal atrial fibrillation. The novel catheter design enhances efficiency with a large, conformable tip that delivers pulsed field energy without requiring multiple rotations at one location. In a trial involving 85 patients, the catheter achieved an 81.8% freedom from atrial arrhythmias after one year and showed a very favorable safety profile. This advancement may significantly impact AFib treatment as patient need for innovative catheter solutions grows.
Read more →MDTSMART trial one-year data demonstrates Medtronic Evolut™ TAVR platform as optimal treatment for severe aortic stenosis in patients with small annulus, which is primarily women Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of...
Medtronic announced one-year data from the SMART Trial, the largest head-to-head study of TAVR systems for patients with small aortic annuli, primarily women. The study showed that the Evolut TAVR platform has non-inferior clinical outcomes and superior performance over the SAPIEN platform. This trial emphasizes the necessity of tailoring treatment for underrepresented groups and addresses the specific needs of women suffering from severe aortic stenosis. The findings are expected to guide clinicians in valve selection for optimal patient outcomes.
Read more →MDTNew survey uncovers lack of awareness around heart valve disease and risk factors among women Medtronic plc, a global leader in healthcare technology, today unveiled topline findings of its comprehensive survey on women's perceptions and...
Medtronic plc has released findings from a survey revealing a concerning lack of awareness about heart valve disease and associated risks among women aged 50 and older in the U.S. The survey indicates that despite prevalence, many women have not been referred to cardiologists or educated on symptoms such as aortic stenosis. Notably, racial disparities in awareness were observed, with women of color showing significantly lower levels of knowledge about cardiovascular conditions. Medtronic aims to address these issues through partnerships and initiatives focused on improving health equity and patient education.
Read more →MDTMedtronic announces FDA approval of newest-generation Evolut TAVR system for treatment of symptomatic severe aortic stenosis Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has...
Medtronic plc has announced the FDA's approval of their Evolut FX+ transcatheter aortic valve replacement (TAVR) system for patients with symptomatic severe aortic stenosis. The new system enhances coronary access through a larger window design and maintains the proven valve performance of the legacy Evolut platform. It is suitable for patients across all risk categories and aims to improve outcomes for those suffering from this severe condition. The early commercial experience is anticipated in spring 2024, with a full launch expected in summer 2024.
Read more →MDTU.S. Patent Office rejects Axonics' latest challenge to Medtronic patents Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent...
Medtronic announced that the U.S. Patent Trial and Appeal Board has affirmed the validity of two of its patents in a lawsuit against Axonics over sacral neuromodulation technologies. This marks a total of five patents whose validity has now been upheld. Additionally, Medtronic plans to resume its patent infringement litigation in federal court and has filed complaints with the U.S. International Trade Commission to prevent Axonics from importing infringing products. This legal action underpins Medtronic's commitment to protecting its innovations in healthcare technology.
Read more →MDTNew real-world data shows MiniMed™ 780G system sustains strong global performance, exceeding international targets for diabetes management Medtronic plc. (NYSE: MDT), a global leader in healthcare technology, today shared a robust set of new clinical and real-world evidence on the...
Medtronic plc presented new data on the MiniMed™ 780G system at the ATTD conference, demonstrating its capability to exceed international diabetes management targets. The system recorded a Time in Range of 78% and a Time in Tight Range of over 56% among users, indicating significant improvements in blood sugar control. The findings suggest that the MiniMed™ 780G helps enhance quality of life for individuals with type 1 diabetes, achieving high satisfaction rates in the United States. The data emphasizes the transformative potential of automated insulin delivery systems in diabetes care.
Read more →MDTMedtronic announces cash dividend for fourth quarter of fiscal year 2024 The board of directors of Medtronic plc (NYSE: MDT) on Thursday, March 7, 2024, approved the company's cash dividend for the fourth quarter of fiscal ...
Medtronic plc's board of directors has approved a cash dividend of $0.69 per share for the fourth quarter of fiscal year 2024. This decision aligns with previous dividend announcements and underscores Medtronic's status as a Dividend Aristocrat, having raised its dividend for 46 consecutive years. Additionally, the board has authorized $5 billion for share repurchases, enhancing shareholder value. The dividend is set to be paid on April 12, 2024, to eligible shareholders.
Read more →MDTMedtronic EVP & CFO Karen Parkhill to participate in the Barclays healthcare conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 26th annual Barclays global healthcare ...
Medtronic plc (NYSE: MDT) has announced its participation in the upcoming Barclays global healthcare conference scheduled for March 12, 2024. Karen Parkhill, the company's executive vice president and CFO, will be involved in a live Q&A session at 8:00 a.m. EDT. This participation highlights the company's commitment to transparency and investor relations. A live webcast and an archive of the session will be provided for stakeholders.
Read more →MDTMedtronic files ITC action against Axonics to stop unauthorized use of Medtronic innovations Medtronic (NYSE:MDT), the global leader in healthcare technology, today announced it filed a complaint with the U.S. International Trade Commission...
Medtronic has filed a complaint with the U.S. International Trade Commission (ITC) and a parallel lawsuit in the U.S. District Court against Axonics, alleging unauthorized use of its patented technologies for MRI compatibility in implantable medical devices. The company seeks to block Axonics from importing and selling these infringing products in the U.S. Medtronic's executive emphasizes the need for accountability against what they describe as unlawful competition. This legal action follows another infringement suit currently pending in California.
Read more →MDTMedtronic reports third quarter fiscal 2024 financial results Medtronic plc (NYSE:MDT) today announced financial results for its third quarter (Q3) of fiscal year 2024 (FY24), which ended January 26, 2024. Key...
Medtronic plc reported its financial results for the third quarter of fiscal year 2024, showing a 4.7% increase in global revenue compared to the previous year. The company attributed this growth to strong performance across various segments, including Diabetes and Cardiovascular divisions. Medtronic raised its full-year revenue and EPS guidance, reflecting confidence in future growth prospects. However, the company experienced flat non-GAAP net income, and it announced plans to exit its ventilator product line due to unprofitability.
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2024 financial results Delivers on co
Medtronic plc announced its third quarter fiscal 2024 financial results, showcasing a revenue of $8.1 billion, reflecting a 4.7% increase. The company has raised its full-year guidance for organic revenue growth and diluted earnings per share following strong performance across various portfolios, particularly in Diabetes and Cardiovascular businesses. Medtronic received several product approvals, enhancing its market position. However, the company is exiting its ventilator product line due to unprofitability, impacting its overall revenue in that segment.
Read more →MDTMedtronic to announce financial results for its third quarter of fiscal year 2024 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of...
Medtronic plc (NYSE: MDT) has announced that it will report its financial results for the third quarter of fiscal year 2024 on February 20, 2024. A news release providing summary financial information will be available that morning, followed by a video webcast to discuss the results. This event will be part of Medtronic's ongoing commitment to transparency in its financial reporting, with additional future quarters already scheduled for release in 2024 and 2025.
Read more →MDTFDA approves Medtronic Percept™ RC neurostimulator with exclusive BrainSense™ technology Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval of its...
Medtronic plc has received FDA approval for its Percept™ RC Deep Brain Stimulation (DBS) system, marking a significant advancement in neuromodulation technology. This rechargeable neurostimulator is part of the Percept™ family, distinguished as the only sensing-enabled DBS system currently available. With its advanced BrainSense™ technology, the device captures and records brain activity, allowing healthcare providers to personalize treatment for patients suffering from Parkinson's disease and other movement disorders. Medtronic aims to continuously innovate and improve therapy outcomes for patients through this groundbreaking technology.
Read more →MDTMedtronic Diabetes announces world's first approval for MiniMed™ 780G System with Simplera Sync™ disposable, all-in-one sensor Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for the MiniMed™ 780G...
Medtronic plc has received CE Mark approval for its MiniMed™ 780G insulin delivery system equipped with the new Simplera Sync™ disposable glucose sensor. This system simplifies glucose monitoring with a two-step insertion process and eliminates the need for fingersticks. Expected to launch in Europe in spring 2024, the MiniMed™ 780G system aims to enhance diabetes management through automatic glucose level adjustments and innovative features designed to reduce post-meal hyperglycemia. The introduction of this advanced system follows positive real-world performance data from previous models.
Read more →MDTMedtronic receives CE Mark for its next generation Micra leadless pacing systems Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received CE (Conformité Européenne) Mark for its Micra™...
Medtronic plc has received CE Mark for its next generation Micra AV2 and Micra VR2 leadless pacemakers, offering nearly 40% longer battery life compared to previous models. These devices are the smallest pacemakers available, and their new features include remote monitoring, which reduces the need for patients to attend in-person appointments. The approval follows FDA clearance in 2023, indicating a strong market position for Medtronic in advanced cardiac pacing solutions.
Read more →MDTMedtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 42nd annual J.P. Morgan healthcare...
Medtronic plc (NYSE: MDT) announced its participation in the 42nd annual J.P. Morgan healthcare conference scheduled for January 8, 2024. CEO Geoff Martha will present and engage in a Q&A session alongside other executives. The event highlights Medtronic's ongoing commitment to addressing challenging health problems through innovative healthcare technology. A live webcast will be available for interested audiences, showcasing the company's strategic vision and operations.
Read more →MDTMedtronic creates history with FDA approval of its novel PulseSelect™ Pulsed Field Ablation System to treat atrial fibrillation Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has...
Medtronic plc has received FDA approval for its PulseSelect Pulsed Field Ablation System, a significant advancement in the treatment of atrial fibrillation. This system, the first of its kind to gain FDA approval, promises improved safety and efficacy for patients, with 80% clinical success rates. The upcoming commercialization in early 2024 further aims to enhance patient access to this groundbreaking technology. The PulseSelect System is also designed to integrate seamlessly into clinical workflows, further aiding healthcare professionals in their treatments.
Read more →MDTMedtronic and Cosmo Pharmaceuticals forge ahead in AI-driven care Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announces that it has entered into a definitive agreement to expand its...
Medtronic has entered a definitive agreement to expand its partnership with Cosmo Pharmaceuticals, focusing on AI-driven enhancements in endoscopy. This includes the development of the AI Access platform, which supports multiple third-party AI applications. The collaboration aims to improve patient outcomes through advanced diagnostic tools, leveraging the successes achieved with the GI Genius module. Medtronic will invest $100 million upfront, along with royalties on net sales and milestone payments to Cosmo, establishing a strong financial commitment to this transformative venture.
Read more →MDTMedtronic announces cash dividend for third quarter of fiscal year 2024 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of...
Medtronic plc's board of directors has approved a cash dividend of $0.69 per ordinary share for the third quarter of fiscal year 2024. This decision follows a previously announced dividend increase in May 2023 and reinforces the company's status as a consistent performer in shareholder returns. Medtronic has a notable history as a Dividend Aristocrat, having raised its annual dividend for 46 consecutive years. The dividend will be payable on January 12, 2024, to shareholders recorded by December 20, 2023.
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2024 financial results Solid executi
Medtronic plc reported its second quarter financial results for FY24, revealing a revenue increase of 5.3% to $8.0 billion. The company has strong underlying business fundamentals, with broad-based growth across various sectors and geographical markets. Significant FDA approvals for new products were highlighted, which contribute positively to the company's long-term growth outlook. However, challenges such as minor declines in non-GAAP EPS and customer attrition in the diabetes segment were noted.
Read more →MDTMedtronic reports second quarter fiscal 2024 financial results Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key...
Medtronic plc (NYSE: MDT) disclosed its financial results for Q2 FY24, highlighting a 5.3% increase in worldwide revenue totaling $7.984 billion. The revenue growth was attributed to broad-based strengths within its diverse portfolio, particularly in cardiovascular and diabetes sectors. Notably, Medtronic raised its fiscal year guidance for both organic revenue growth and diluted EPS, reflecting confidence in its performance amid regulatory approvals and product launches. However, challenges remain, including a decrease in non-GAAP net income and diluted EPS due to foreign currency impact.
Read more →MDTMedtronic announces FDA approval of minimally invasive device to treat hypertension Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that the United States Food and Drug Administration (FDA) has...
Medtronic has received FDA approval for its Symplicity Spyral renal denervation system, a minimally invasive procedure designed to treat hypertension. This innovative treatment, developed over ten years of research, aims to address the global health issue of high blood pressure, particularly in underserved populations. The procedure uses radiofrequency energy to calm overactive nerves near the kidneys, which can contribute to high blood pressure. With the approval, Medtronic will begin commercializing the technology, marking a significant milestone in hypertension management.
Read more →MDTA majority of Americans are optimistic that AI will improve healthcare in 2024 More than half (51%) of U.S. adults are optimistic new applications of artificial intelligence (AI) will lead to major advancements and breakthroughs ...
A recent survey by Medtronic and Morning Consult reveals that over half of Americans, 51%, are optimistic about new AI applications improving healthcare in 2024. Respondents particularly highlight the potential of AI for earlier diagnoses and enhancing access to care, with 61% supporting AI's utility in detecting conditions. However, while optimism is strong, skepticism persists, particularly regarding the replacement of human doctors and the need for more demonstrable proof of AI's benefits in healthcare settings. Discussions around AI's role in medicine will continue at the upcoming Techonomy23 conference.
Read more →MDTMedtronic to announce financial results for its second quarter of fiscal year 2024 Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of...
Medtronic plc (NYSE: MDT) has announced it will release its financial results for the second quarter of fiscal year 2024 on November 21, 2023. The results will cover the period ending October 27, 2023, and a video webcast is scheduled for 7:00 a.m. CST on the same day to discuss these results. Additionally, the company has planned to report financial outcomes for the third and fourth quarters on February 20, 2024, and May 23, 2024, respectively. All information will be accessible on Medtronic's investor relations website.
Read more →MDTMedtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year results from the Evolut Low Risk Trial. The Medtronic...
Medtronic plc announced promising four-year results from the Evolut Low Risk Trial, highlighting the Evolut transcatheter aortic valve replacement (TAVR) system's superiority over surgical aortic valve replacement (SAVR). The study found a 26% relative reduction in the risk of death or disabling stroke for TAVR patients. Additionally, TAVR patients experienced lower rehospitalization rates compared to those undergoing SAVR. These findings underscore Medtronic's commitment to enhancing patient care with their innovative TAVR technology for low-risk symptomatic severe aortic stenosis patients.
Read more →MDTMedtronic receives FDA approval for extravascular defibrillator to treat abnormal heart rhythms, sudden cardiac arrest Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora...
Medtronic plc has received FDA approval for the Aurora EV-ICD system, a groundbreaking extravascular defibrillator designed to treat abnormal heart rhythms and sudden cardiac arrest. This device is distinguished by its unique lead placement outside of the heart and veins, which may reduce long-term complications associated with traditional ICDs. Clinical trial results highlighted an impressive 98.7% effectiveness rate, and the device's commercial availability in the U.S. is expected soon. With additional features for patient comfort and safety, this advancement underscores a significant evolution in implantable defibrillator technology.
Read more →MDTMedtronic Diabetes announces CE Mark for new Simplera™ CGM with disposable all-in-one design Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for its new all-in-one,...
Medtronic plc has received CE Mark approval for its new Simplera™ continuous glucose monitor (CGM), which features a compact, all-in-one design and a simple insertion process. This new system aims to enhance the user experience and is compatible with both iOS and Android, though it is currently not FDA-approved and limited to investigational use in the U.S. The launch is set to begin at the upcoming EASD Annual Meeting in Hamburg, Germany. Medtronic emphasizes its commitment to improving diabetes management and aims to help more patients meet their glycemic targets with the Simplera™ system.
Read more →MDTMedtronic receives CE Mark approval for Inceptiv™ spinal cord stimulator with closed-loop sensing to treat chronic pain Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received CE (Conformité Européenne) Mark approval for its Inceptiv™...
Medtronic plc has received CE Mark approval for its Inceptiv closed-loop rechargeable spinal cord stimulator, which adjusts therapy based on real-time signals from the spinal cord. This innovative device senses the patient's biological signals, thus optimizing pain relief therapy during daily activities. In a clinical study, a significant majority of patients preferred the closed-loop feature compared to traditional fixed-output stimulators. The Inceptiv device is set to become commercially available in Europe in the coming months, although it is not yet cleared for U.S. distribution.
Read more →MDTMedtronic issues statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System Today, Medtronic announced the outcome of the U.S. Food & Drug Administration (FDA) Circulatory System Devices Panel (CSDP) meeting to review data...
Medtronic announced the results of the FDA Circulatory System Devices Panel meeting regarding its Symplicity Spyral Renal Denervation (RDN) System. The panel unanimously voted on the device's safety, while the effectiveness vote was narrowly approved with a 7-6 outcome. The chair of the panel broke a tie on the benefit/risk profile, reflecting some level of uncertainty. Medtronic expresses gratitude for the discussions and intends to collaborate with the FDA as they pursue U.S. market approval for the device.
Read more →MDTMedtronic to participate in upcoming investor conferences Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today confirmed its participation in the following upcoming investor conferences: ...
Medtronic plc has announced its participation in several upcoming investor conferences, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference. CEO Geoff Martha and CFO Karen Parkhill will represent the company in discussions about the medtech industry and its own business operations. Each conference will include live webcasts of Q&A sessions, allowing for greater accessibility to investors and stakeholders. This engagement underscores Medtronic's commitment to maintaining transparency within the healthcare technology sector.
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2024 financial results Broad strength
Medtronic plc reported its first quarter fiscal 2024 financial results, showing a revenue increase of 4.5%, reaching $7.7 billion. The company experienced broad strength across its businesses and geographies, with the Diabetes and Cardiovascular portfolios driving significant growth. Additionally, Medtronic raised its FY24 organic revenue growth and EPS guidance following its strong performance. The launches of new medical devices and the positive feedback on their latest systems contributed to the optimistic outlook for the fiscal year.
Read more →MDTMedtronic reports first quarter fiscal 2024 financial results Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2024 (FY24), which ended July 28, 2023. Key...
Medtronic plc announced its fiscal year 2024 first quarter financial results, revealing a worldwide revenue of $7.702 billion, representing a 4.5% increase. The company experienced broad revenue growth across its four segments, each achieving an organic growth rate of 6%. Despite the revenue growth, GAAP net income decreased by 15%, prompting concerns about earnings quality. Medtronic has raised its revenue growth and EPS guidance for FY24, indicating strong operational performance and improved fundamentals.
Read more →MDTMedtronic announces cash dividend for second quarter of fiscal year 2024 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 17, 2023, approved an increase in the company's cash dividend for the second...
Medtronic plc has announced an increase in its cash dividend for the second quarter of fiscal year 2024 to $0.69 per ordinary share, reflecting a year-over-year rise. This announcement aligns with previous dividend declarations made earlier in the year. Medtronic's long-standing history as a dividend aristocrat is emphasized, highlighting its commitment to consistent dividend payments over the past 46 years. The upcoming payment will be issued on October 13, 2023, to eligible shareholders.
Read more →MDTMedtronic to announce financial results for its first quarter of fiscal year 2024 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of...
Medtronic plc has announced its schedule for reporting financial results for the first quarter of the fiscal year 2024, which will occur on August 22, 2023. A news release containing summary financial information will be issued, followed by a video webcast to discuss the results. Future reporting dates for subsequent quarters have also been outlined. Medtronic positions itself as a leader in healthcare technology, focusing on innovative solutions for various health conditions.
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Greg Lewis as new Director DUBLIN
Medtronic has appointed Greg Lewis, the CFO of Honeywell, to its Board of Directors, effective June 26, 2023. Lewis will serve on both the Audit Committee and the Finance and Financial Risk Committee. Company leaders express that his financial expertise will significantly benefit Medtronic as it undergoes a comprehensive transformation aimed at achieving sustainable growth. Lewis acknowledges the company's mission and looks forward to contributing to its progress.
Read more →MDTMedtronic Board appoints Greg Lewis as new Director Medtronic announced today that its Board of Directors appointed Greg Lewis, Senior Vice President and Chief Financial Officer at Honeywell, to the...
Medtronic announced the appointment of Greg Lewis as a new director on its Board, effective June 26, 2023. Lewis, who is the Senior Vice President and Chief Financial Officer at Honeywell, will also serve on the Audit Committee and the Finance and Financial Risk Committee. The leadership at Medtronic is optimistic that his financial expertise will aid in the company's transformation and growth strategy. Lewis expressed enthusiasm about joining the company and contributing to its mission of improving health outcomes.
Read more →MDTMedtronic presents new data on MiniMed™ 780G system on fixed meal dosing and real-world Time in Range across wide variety of users Medtronic plc (NYSE: MDT), a global leader in healthcare technology, is presenting a robust collection of new clinical and real-world data on the...
Medtronic presented new clinical and real-world data on its MiniMed™ 780G insulin delivery system, showcasing improved outcomes among a diverse user base, including younger patients and those traditionally not meeting glycemic targets. The data indicates that the use of simplified meal announcements enhances Time in Range and reduces hyperglycemia. Notably, real-world evidence showed a Time in Range of 78% for children aged 15 and younger, with a significant reduction in time above hyperglycemic thresholds. Overall, these findings suggest that the MiniMed™ 780G system supports a more manageable diabetes management approach for users.
Read more →MDTMedtronic to present new data on its intelligent dosing platforms at the American Diabetes Association 83rd Scientific Sessions Medtronic plc (NYSE:MDT), a global leader in medical technology, today announced its participation in the upcoming American Diabetes Association's...
Medtronic plc is set to present new data at the American Diabetes Association's 83rd Scientific Sessions, taking place from June 23-26, 2023. The company will showcase its MiniMed™ 780G system, including clinical outcomes from recent studies that demonstrate its advantages over traditional insulin delivery methods. Medtronic will also host an analyst and investor briefing to discuss its Diabetes business initiatives. This presentation will include insights into the effectiveness of next-generation sensors and automated insulin delivery systems.
Read more →MDTMedtronic names Ken Washington new Chief Technology and Innovation Officer Medtronic plc (NYSE:MDT) today announced that Ken Washington, Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer. In this...
Medtronic plc has appointed Ken Washington, Ph.D., as its new Chief Technology and Innovation Officer. In this newly established position, Dr. Washington will utilize his extensive experience in sectors such as robotics and automotive to foster innovation and growth. His role aims to enhance Medtronic's use of technology platforms, driving advances in healthcare technology. Washington previously held leadership roles at Amazon and Ford, showcasing a strong background that aligns with Medtronic’s mission to improve health outcomes.
Read more →MDTMedtronic chairman and CEO Geoff Martha to speak at Goldman Sachs global healthcare conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 44th annual Goldman Sachs global...
Medtronic plc (NYSE: MDT) announced its participation in the 44th annual Goldman Sachs global healthcare conference on June 12, 2023. CEO Geoff Martha will host a Q&A session at 10:40 a.m. PDT. A live webcast will be accessible to the public, reflecting the company's commitment to transparency and engagement with investors and stakeholders.
Read more →MDTMedtronic reports full year and fourth quarter fiscal 2023 financial results; announces dividend increase Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2023, which ended April 28, 2023. Fourth Quarter...
Medtronic plc announced its financial results for Q4 and fiscal year 2023, reporting a 5.6% increase in Q4 revenue to $8.544 billion, surpassing expectations. Key highlights include notable growth across its Cardiovascular, Medical Surgical, and Neuroscience portfolios, alongside a declared dividend increase of 46 years of consecutive growth. However, the company experienced declines in GAAP net income and earnings per share, primarily affected by unfavorable macroeconomic conditions. For fiscal year 2024, Medtronic forecasts organic revenue growth of 4.0% to 4.5%, indicating confidence in its operational recovery and market position.
Read more →MDTMedtronic to acquire wearable insulin patch maker EOFlow Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a set of definitive agreements to acquire...
Medtronic plc has announced its definitive agreement to acquire EOFlow Co. Ltd., the manufacturer of the EOPatch insulin delivery device. This acquisition is aimed at enhancing Medtronic's diabetes management offerings by integrating EOFlow’s technology with its established Meal Detection Technology™ and continuous glucose monitors. The EOPatch device, already authorized for marketing in various regions, is designed to make insulin delivery more convenient for users. The transaction, expected to close in the second half of 2023, is anticipated to be largely neutral to Medtronic's earnings per share and support its long-term growth trajectory.
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal 2023 financial results
Medtronic plc reported its fourth quarter and full fiscal year 2023 financial results, marking a positive finish with a 5.6% revenue increase in Q4, ahead of expectations. The company announced a dividend increase, highlighting 46 consecutive years of dividend growth. However, despite these gains, there were noticeable declines in diluted earnings per share and overall revenue for the fiscal year, impacted by foreign currency translation and the divestiture of its Renal Care Solutions unit. The company maintained a optimistic outlook driven by product innovations and international market strength.
Read more →MDTMedtronic Extravascular ICD global clinical trial results reinforce device safety and effectiveness Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced longer-term follow-up results of its investigational EV ICD™ System,...
Medtronic has announced positive long-term results from its investigational EV ICD™ system, designed for treating fast heart rhythms and avoiding risks typical of traditional systems. The findings, presented at Heart Rhythm 2023, indicate a 91.9% safety rate for major complications, with effective therapy documented in multiple patients over an average of 17 months. However, the device remains investigational and is not yet available in the U.S., with some patients experiencing lead dislodgment and inappropriate shocks.
Read more →MDTMedtronic AccuRhythm AI technology receives 2023 MedTech Breakthrough Award as Best New Monitoring Solution Medtronic plc (NYSE: MDT) today announced its AccuRhythm™ AI algorithm technology is the winner of the 7th annual MedTech Breakthrough Awards program ...
Medtronic plc (NYSE: MDT) has announced that its AccuRhythm AI technology won the MedTech Breakthrough Award for 'Best New Monitoring Solution'. This award recognizes the technology's contribution to enhancing the accuracy of monitoring heart rhythm events and reducing false alerts. The AccuRhythm AI algorithms, first introduced in 2022, are expected to improve patient care and clinician efficiency significantly. FDA clearance has also been obtained to expand these algorithms to the Reveal LINQ ICM, facilitating better long-term monitoring for patients.
Read more →MDTMedtronic to announce financial results for its fourth quarter and full fiscal year 2023 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and...
Medtronic plc has announced plans to report its financial results for the fourth quarter and full fiscal year 2023 on May 25, 2023. A news release detailing summary financial information will be made available shortly after the market opens. Additionally, the company will host a video webcast at 7:00 a.m. CDT on the same day to discuss the results. Medtronic is also scheduling dates for its fiscal year 2024 financial results to strengthen its investor relations.
Read more →MDTMedtronic receives FDA approval for its next generation Micra leadless pacing systems Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) approval ...
Medtronic has received FDA approval for its Micra AV2 and Micra VR2 leadless pacemakers, which are designed to enhance patient care. These devices feature 40% improved battery life, with a projected lifespan of up to 17 years. Incorporating advanced algorithms for better synchronization of heart chambers, the Micra devices aim to minimize surgical interventions and complications associated with traditional pacemakers. This approval reinforces Medtronic's leadership in innovative cardiac technologies.
Read more →MDTMedtronic Diabetes resolves warning letter, clearing path for future innovations Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) lifted the...
Medtronic plc (NYSE: MDT) has announced that the FDA has lifted a warning letter related to its Diabetes headquarters, following remediation efforts. This resolution coincides with the FDA's approval of the MiniMed 780G system, which is described as the first automated insulin delivery system with meal detection technology. The approval allows Medtronic to focus on delivering innovations aimed at improving the lives of individuals with diabetes. Medtronic's commitment to quality and patient safety remains a priority as they advance their diabetes management technologies.
Read more →MDTFDA Approves Medtronic MiniMed™ 780G System - World's First Insulin Pump with Meal Detection Technology* Featuring 5-Minute Auto Corrections†§ Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its MiniMed™...
Medtronic has received FDA approval for its MiniMed 780G insulin pump, the first to feature meal detection technology capable of automatic insulin adjustments every five minutes. This system is designed for users with type 1 diabetes, aiming to simplify blood sugar management and enhance the user experience. With high satisfaction rates reported among users, the device is a significant advancement in diabetes care. Pre-orders will begin on May 15, 2023, with initial shipments expected later in the summer.
Read more →MDTMedtronic, DaVita launch Mozarc Medical, aimed at introducing new solutions for patients with kidney failure Medtronic plc (NYSE: MDT) and DaVita Inc. (NYSE: DVA) today announced the launch of Mozarc Medical—an independent new company committed to reshaping...
Medtronic plc and DaVita Inc. have announced the launch of Mozarc Medical, an independent company focused on kidney health technologies. Led by industry veterans, Mozarc Medical aims to improve patient experiences and access to care globally, particularly in home dialysis. The initiative combines the strengths of both parent companies to develop patient-centered solutions and enhance clinical performance. This venture represents a significant step in addressing the evolving needs of patients with kidney disease.
Read more →MDTMedtronic Announces Pricing of $2.0 Billion of Senior Notes Medtronic plc (the Company ) (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ( Medtronic Luxco ), has ...
Medtronic plc has announced a successful pricing of $2 billion in senior notes through its subsidiary, Medtronic Global Holdings. The offering consists of $1 billion in notes due 2028 and $1 billion in notes due 2033, with proceeds earmarked for debt repayment and general corporate purposes. The offering is set to close on March 30, 2023, subject to customary conditions. This move is part of Medtronic's ongoing strategy to maintain financial health and support its growth objectives.
Read more →MDTMedtronic to boost AI innovation with new platform introduction Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced Cosmo Pharmaceuticals and NVIDIA plan to integrate NVIDIA's AI...
Medtronic plc has announced a strategic partnership with Cosmo Pharmaceuticals and NVIDIA to introduce the AI Access platform, enhancing its GI Genius intelligent endoscopy module. This collaboration intends to integrate advanced AI technologies to improve the detection of polyps during colonoscopy procedures. The launch coincides with the inaugural Medtronic GI Genius summit, showcasing future AI innovations and ethical considerations in clinical practice. The initiative promises to support developers and potentially enhance patient outcomes in gastrointestinal care.
Read more →MDTMedtronic receives CE Mark approval for Affera™ Mapping and Ablation System to treat atrial arrhythmias Medtronic (NYSE:MDT) announced today that it has received CE (Conformité Européenne) Mark for the Affera™ Mapping and Ablation System, which includes ...
Medtronic has obtained CE Mark approval for its Affera Mapping and Ablation System, which features the Sphere-9 Catheter and Affera Prism-1 Mapping Software. This all-in-one system integrates pulsed field ablation, radiofrequency, and high-density mapping for effectively treating atrial arrhythmias, including atrial fibrillation. The Sphere-9 Catheter is designed to enhance procedure efficiency by potentially reducing the number of ablation applications required. The system will be commercially available in Europe starting in the first half of 2023, while its investigational status remains in the United States.
Read more →MDTMEDTRONIC ERHÄLT CE-KENNZEICHNUNG FÜR DAS AFFERA™ MAPPING- UND ABLATIONSSYSTEM ZUR BEHANDLUNG ATRIALER ARRHYTHMIEN Medtronic (NYSE:MDT) gab heute bekannt, dass das Unternehmen die CE-Kennzeichnung (Conformité Européenne) für das Affera™ Mapping- und...
Medtronic has announced that it has received CE marking for its Affera Mapping and Ablation System, which includes the Sphere-9 catheter and Affera Prism-1 mapping software. This innovative system combines pulsed field ablation and high-frequency ablation, enabling real-time feedback for treating atrial tachyarrhythmias. As the market for electrophysiology rapidly evolves, this new offering is expected to enhance patient care and procedural efficiency. The system will be available in Europe in early 2023 and is currently in the testing phase in the U.S.
Read more →MDTMedtronic named one of World's Most Ethical Companies Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has been recognized by Ethisphere, a leader in defining and advancing the...
Medtronic plc has been named one of the 2023 World's Most Ethical Companies by Ethisphere, reflecting its commitment to ethical business practices in healthcare technology. The recognition honors 135 companies from 19 countries and signifies Medtronic's distinction as one of only two companies in the Healthcare Products sector. Medtronic's success in this assessment is attributed to its dedication to integrity, governance, and corporate citizenship as expressed by its leadership. This acknowledgment is part of a broader initiative to promote high standards in business ethics across various industries.
Read more →MDTMedtronic PulseSelect PFA System demonstrates impressive results in landmark PULSED AF global IDE trial Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its PulseSelect™ Pulsed Field Ablation (PFA) System...
Medtronic plc announced positive results from its PulseSelect Pulsed Field Ablation (PFA) System in the PULSED AF trial, which exceeded safety and efficacy performance goals for treating paroxysmal and persistent atrial fibrillation. The trial, involving 300 patients across multiple countries, reported a low adverse event rate of 0.7% and over 80% clinical success in both patient cohorts. This pioneering study is considered a significant advancement in PFA technology, enhancing treatment options for patients with atrial fibrillation.
Read more →MDTMedtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2023 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 2, 2023, approved the fiscal year 2023 fourth quarter cash dividend of $0.68...
Medtronic plc (NYSE: MDT) announced an increase in its fiscal year 2023 fourth quarter cash dividend to $0.68 per ordinary share, reflecting an 8% rise over the previous year. This dividend declaration aligns with the company's commitment to returning value to shareholders, as evidenced by its consistent annual dividend increase for 45 consecutive years. Shareholders of record as of March 24, 2023, will receive the dividend payable on April 14, 2023.
Read more →MDTMedtronic Executive Vice President and CFO Karen Parkhill to speak at Cowen healthcare conference Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual Cowen healthcare...
Medtronic plc has announced its participation in the 43rd annual Cowen healthcare conference set for March 6, 2023. Karen Parkhill, the executive vice president and chief financial officer, will engage in a Q&A session at the event. A live webcast of the session will be available for attendees, emphasizing Medtronic's commitment to transparency and stakeholder engagement. The company, a leader in healthcare technology, aims to address significant health challenges globally.
Read more →MDTMiniMed™ 780G system demonstrates superiority over multiple daily injections with CGM for type 1 diabetes management at one-year in ADAPT study Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced one-year data from the ADAPT study (n=82), the first...
Medtronic plc announced positive one-year results from the ADAPT study, demonstrating that its MiniMed 780G advanced hybrid closed loop system significantly outperformed multiple daily injections of insulin with intermittently scanned continuous glucose monitoring. The study, which included participants not meeting glycemic targets, showed an impressive 27.6% increase in Time in Range and a 1.4% decrease in HbA1c levels after six months. The findings suggest that automated insulin delivery systems could enhance diabetes management earlier in treatment, supporting Medtronic's commitment to improving patient outcomes.
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2023 financial results Deliv
Medtronic plc reported its third quarter fiscal 2023 financial results, revealing a flat revenue of $7.7 billion but a 4.1% organic growth, surpassing expectations. The company’s strong performance in its Cardiovascular and Neuroscience portfolios drove this growth, while challenges remained in specific markets like China. Despite a decline in net income and earnings per share, Medtronic maintains an optimistic outlook, projecting durable revenue growth in the future. The company also plans to execute strategic initiatives to recover revenues from impacted sectors.
Read more →MDTMedtronic reports third quarter fiscal 2023 financial results Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2023, which ended January 27, 2023. Key Highlights...
Medtronic plc reported its third quarter fiscal 2023 financial results, highlighting a return to mid-single digit organic growth driven by strong performances in its Cardiovascular and Neuroscience portfolios. The company's worldwide revenue reached $7.727 billion, with an organic increase of 4.1%. However, it faced challenges including significant decreases in GAAP net income and diluted earnings per share, alongside revenue pressures in China and continuing foreign currency impacts. Despite these challenges, Medtronic updated its guidance for improved revenue growth moving forward.
Read more →MDTMedtronic Receives CE Mark for Extravascular Defibrillator System That Treats Abnormal Heart Rhythms Medtronic plc (NYSE:MDT) has received CE (Conformité Européenne) Mark for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable...
Medtronic has been granted CE Mark approval for its Aurora EV-ICD MRI SureScan, an innovative extravascular implantable cardioverter-defibrillator. This system offers the critical benefits of traditional ICDs while placing leads outside the heart and veins, mitigating risks of long-term complications. Clinical studies have demonstrated a high success rate for defibrillation therapy with this device. The Aurora EV-ICD is expected to be available in select European countries by autumn 2023.
Read more →MDTMedtronic to announce financial results for its third quarter of fiscal year 2023 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of...
Medtronic plc (NYSE: MDT) will announce its financial results for the third quarter of fiscal year 2023 on February 21, 2023. The announcement will be followed by a video webcast at 7:00 a.m. CST to discuss the outcomes. Additionally, the company has outlined its reporting schedule for the upcoming fiscal year, highlighting its ongoing commitment to transparency and communication with investors.
Read more →MDTMedtronic LINQ Insertable Cardiac Monitor detects 10 times more atrial fibrillation in ischemic stroke patients at three years compared to standard of care Medtronic (NYSE: MDT) today announced late-breaking clinical data from the STROKE AF clinical study, which showed large and small vessel disease...
Medtronic has announced late-breaking clinical results from its STROKE AF study, demonstrating a significant increase in atrial fibrillation (AF) detection among ischemic stroke patients using its Reveal LINQ insertable cardiac monitor (ICM). At three years, AF detection rose to 21.7% in the ICM group compared to only 2.4% in the standard care group. The data emphasizes the importance of long-term monitoring, especially since many episodes were asymptomatic. This study underscores the potential of ICMs in improving outcomes for stroke patients who may otherwise miss critical AF diagnoses.
Read more →MDTMedtronic continues to make significant advances as an Inclusion, Diversity & Equity leader Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced that it joins 483 other global companies as a member of the 2023...
Medtronic plc (NYSE: MDT) has been named a member of the 2023 Bloomberg Gender-Equality Index, joining 483 other companies globally. The company also released its Global Inclusion, Diversity & Equity (ID&E) 2022 Annual Report, emphasizing their commitment to creating a diverse and equitable workplace. Medtronic's leaders underscored that innovation depends on removing barriers and empowering employees from diverse backgrounds to contribute effectively. This recognition highlights Medtronic's ongoing efforts to integrate ID&E principles throughout its operations.
Read more →MDTMedtronic recommends rejection of below-market mini-tender offer by TRC Capital Investment Corporation Medtronic plc (NYSE:MDT) recently became aware that TRC Capital Investment Corporation (TRC) has made an unsolicited mini-tender offer to purchase up ...
Medtronic plc has advised its shareholders to reject an unsolicited mini-tender offer from TRC Capital Investment Corporation, which seeks to purchase up to 1,500,000 ordinary shares at a price significantly below the current market value. The company's shares closed at $80.91, while TRC's offer was for $77.25, representing a 4.5% discount. Medtronic emphasized that shareholders should remain cautious and not take action on the offer, which is set to expire on February 22, 2023. Shareholders already tendering their shares were advised to withdraw before the expiration date.
Read more →MDTMedtronic named one of America's Most JUST Companies by JUST Capital and CNBC Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has been named to the 2023 Rankings of America's Most JUST Companies by JUST...
Medtronic plc has been included in the 2023 Rankings of America's Most JUST Companies as established by JUST Capital and CNBC. This recognition underscores the company's commitment to its employees, customers, and communities. Medtronic's long-standing mission to improve lives has guided its efforts in achieving this designation. The JUST Rankings evaluate companies based on their performance in critical areas related to responsible corporate behavior, reflecting public sentiment on what matters in corporate responsibility today.
Read more →MDTMedtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 41st annual J.P. Morgan healthcare...
DUBLIN , Dec. 19, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it will participate in the 41st annual J.P. Morgan healthcare conference. Geoff Martha , Medtronic chairman and chief executive officer, will make a forma
Read more →MDTMedtronic announces first patient enrolled in U.S. clinical trial for Hugo™ robotic-assisted surgery system Medtronic plc (NYSE: MDT), a global healthcare technology leader, today announced the first patient enrolled in the Expand URO U.S. clinical trial...
Expand URO is a prospective, multi-center, single-arm study to evaluate the safety and performance of the Hugo™ RAS system for urologic procedures DUBLIN , Dec. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global healthcare technology leader, today announced the first
Read more →MDTMedtronic named as a leading sustainability company Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced its continued inclusion in the Dow Jones® Sustainability World...
Strong environmental, social, and governance (ESG) management and performance result in continued inclusion on the Dow Jones Sustainability World Index DUBLIN , Dec. 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it
Read more →MDTMedtronic announces cash dividend for third quarter of fiscal year 2023 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68...
DUBLIN , Dec. 8, 2022 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT ) on Thursday, December 8, 2022, approved the fiscal year 2023 third quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly declara
Read more →MDTMedtronic completes enrollment in pivotal trial evaluating first-of-its-kind pulsed field ablation catheter for patients with atrial fibrillation Medtronic (NYSE:MDT) today announced the completion of enrollment and final treatment in the SPHERE Per-AF Trial, a U.S. Food and Drug Administration ...
SPHERE Per-AF will determine the safety and effectiveness of the Sphere-9 cardiac ablation and mapping catheter with the Affera mapping and navigation system DUBLIN , Dec. 5, 2022 /PRNewswire/ -- Medtronic (NYSE: MDT ) today announced the completion of enrollment and final treat
Read more →MDTMedtronic executives to speak at the Evercore ISI 5th annual HealthCONx conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Evercore ISI 5th annual HealthCONx...
DUBLIN , Nov. 23, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it will participate in the Evercore ISI 5 th annual HealthCONx conference on Tuesday, November 29 , 2022. Geoff Martha , Medtronic chairman and chief exec
Read more →MDT▼ -5.3%on this newsshared move
Document NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2023 financial results Earn
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 Medtronic reports second quarter fiscal 2023 financial results Earnings delivered despite slower market procedure volume and supply recovery Growth driven
Read more →MDT▼ -5.3%on this newsshared move
Medtronic reports second quarter fiscal 2023 financial results Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2023, which ended October 28, 2022. Key Highlights...
Earnings delivered despite slower market procedure volume and supply recovery; Growth driven by TAVR, Pacing, U.S. Core Spine, and International Diabetes DUBLIN , Nov. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its second quarter of
Read more →MDTMedtronic to announce financial results for its second quarter of fiscal year 2023 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of...
DUBLIN , Nov. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2023 on Tuesday, November 22, 2022 . A news release will be issued at approxima
Read more →MDTMedtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in U.S. Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Extended infusion set, the first and ...
Annual costs savings of insulin of up to 25% and plastic waste reduction of up to 50% with Medtronic Extended infusion set DUBLIN , Nov. 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the U.S. launch of Medtronic Ex
Read more →MDTSPYRAL HTN-ON MED study demonstrates meaningful clinical benefits consistent with other SPYRAL HTN renal denervation trials Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON...
DUBLIN and CHICAGO , Nov. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clinical trial. The data were presented today as Late-Breaking Clinical Scie
Read more →MDTLa plataforma Medtronic Neurovascular Co-Lab™ acelerará la innovación en el tratamiento del ictus Medtronic plc (NYSE: MDT), líder mundial en tecnología sanitaria, anunció hoy el lanzamiento de la plataforma Medtronic Neurovascular Co-Lab™,...
La nueva plataforma Medtronic Neurovascular Co-Lab™ impulsa la colaboración y las conexiones entre empresas emergentes, médicos e instituciones; tiene como objetivo mejorar el tratamiento del accidente cerebrovascular y el acceso para los pacientes en todo el mundo DUBLÍN , 26 d
Read more →MDTAnnouncing the launch of Medtronic Neurovascular Co-Lab™ Platform to accelerate innovation in stroke treatment Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of Medtronic Neurovascular Co-Lab™ Platform designed...
New Medtronic Neurovascular Co-Lab ™ Platform drives collaboration and connections among start-ups, physicians, and institutions; aims to improve stroke treatment and access for patients worldwide DUBLIN , Oct. 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader
Read more →MDTAnkündigung der Plattform Medtronic Neurovascular Co-Lab™ zur Beschleunigung der Innovation in der Behandlung von Schlaganfällen Medtronic plc (NYSE: MDT), ein weltweit führender Anbieter von Gesundheitstechnologie, gab heute die Einführung der Plattform Medtronic Neurovascular ...
Neue Plattform Medtronic Neurovascular Co-Lab ™ fördert Zusammenarbeit und Verbindungen zwischen Start-ups, Ärzten und Institutionen und soll Behandlung von Schlaganfällen und Zugang für Patienten weltweit verbessern DUBLIN , Irland , 26. Oktober 2022 /PRNewswire/ -- Medtronic p
Read more →MDTAnnonce du lancement de la plateforme Medtronic Neurovascular Co-Lab™ pour accélérer l'innovation dans le traitement des accidents vasculaires cérébraux Medtronic plc (NYSE: MDT), un leader mondial dans le domaine de la technologie des soins de santé, a annoncé aujourd'hui le lancement de la...
La nouvelle plateforme Medtronic Neurovascular Co-Lab ™ favorise la collaboration et les connexions entre les start-ups, les médecins et les institutions ; elle vise à améliorer le traitement des accidents vasculaires cérébraux et leur accès pour les patients du monde entier DUB
Read more →MDTMedtronic chairman and CEO Geoff Martha to speak at the CECP's CEO Investor Forum Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the Chief Executives for Corporate...
DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it will participate in the Chief Executives for Corporate Purpose's (CECP's) 10 th CEO Investor Forum held at AdvaMed's 2022 MedTech Conference on Tuesday,
Read more →MDTMedtronic announces intention to separate its combined Patient Monitoring and Respiratory Interventions businesses Separation of the combined Patient Monitoring and Respiratory Interventions businesses ( NewCo ) expected to better position both NewCo and Medtronic ...
Separation of the combined Patient Monitoring and Respiratory Interventions businesses ("NewCo") expected to better position both NewCo and Medtronic for long-term success and value creation DUBLIN , Oct. 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in he
Read more →MDTMedtronic expands global access to the benefits of robotic-assisted surgery Medtronic plc (NYSE:MDT), a global healthcare technology leader, has announced three significant global market-entrance and indication expansion...
Hugo™ robotic-assisted surgery system regulatory approval in Japan provides access to third largest robotics market in the world while general surgery approval in the EU and Canada open fast-growing hernia specialty DUBLIN , Oct. 19, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT
Read more →MDTMedtronic leverages data science to launch first-of-its-kind personalized insights program for people living with diabetes Medtronic plc, the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the...
DUBLIN , Oct. 18, 2022 /PRNewswire/ -- Medtronic plc , the global leader in medical technology, is introducing a new program called My Insights exclusively made for individuals using the MiniMed™ 770G system. Using an individual's data, My Insights relies on the power of data sci
Read more →MDTMedtronic first to receive FDA approval for pacing the heart’s natural conduction system Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval for expanded labeling of a cardiac lead...
Medtronic “conduction system pacing” expanded indication now includes left bundle branch area pacing in addition to His-Bundle pacing for patients with slow heart rates DUBLIN , Oct. 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, t
Read more →MDTMedtronic to webcast renal denervation investor & analyst briefing on November 7 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the company will host a webcast to provide an update on its...
DUBLIN , Oct. 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the company will host a webcast to provide an update on its Medtronic Coronary and Renal Denervation business during the American Heart Association annual
Read more →MDTFortune and Great Place to Work® Name Medtronic one of the 'World's Best Workplaces™' in 2022 Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that Great Place to Work® and Fortune magazine have honored...
This is the second notable recognition the company has received this week, following being named to the Fortune 2022 'Change the World' list DUBLIN , Oct. 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that Great Pl
Read more →MDTMedtronic releases 2022 Integrated Performance Report Medtronic plc today released its fiscal year (FY) 2022 Integrated Performance Report: Engineering impact. The report highlights the Company's...
"Engineering impact" highlights the Company's progress toward health equity, workforce diversity and net zero emissions DUBLIN , Oct. 11, 2022 /PRNewswire/ -- Medtronic plc today released its fiscal year (FY) 2022 Integrated Performance Report: Engineering impact. The report hig
Read more →MDTMedtronic announces closing of public offering of €3.5 billion of senior notes Medtronic plc (the Company ) (NYSE: MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ( Medtronic Luxco ) has...
DUBLIN , Sept. 21, 2022 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT ) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ( "Medtronic Luxco") has closed a registered public offering (the "Offering") of €500,000,000 principal amount of 2
Read more →MDTMedtronic receives FDA clearance for expanded indication of LINQ II™ insertable cardiac monitor for use in pediatric patients ages 2 and older Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the...
The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN , Sept. 20, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Mo
Read more →MDTTCT 2022: SYMPLICITY HTN-3 trial data show sustained long-term blood pressure reductions with Medtronic renal denervation procedure Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced long-term results from the SYMPLICITY HTN-3 clinical trial....
DUBLIN and BOSTON , Sept. 18, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced long-term results from the SYMPLICITY HTN-3 clinical trial. Subjects who underwent radiofrequency renal denervation (RF RDN) with the first gen
Read more →MDTMedtronic announces pricing of €3.5 billion of senior notes Medtronic plc (the Company ) (NYSE:MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ( Medtronic Luxco ), has...
DUBLIN , Sept. 15, 2022 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT ) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering (the "Offering") of €500,000,000 principal amount of 2.625% senior not
Read more →MDTMedtronic to appear at September investor conferences Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today confirmed its participation in the following September 2022 investor...
DUBLIN , Sept. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today confirmed its participation in the following September 2022 investor conferences: Wells Fargo 2022 Healthcare Conference Wednesday, September 7, 2022 , at 11:35am E
Read more →MDTMedtronic ADAPT study results published in The Lancet Diabetes & Endocrinology show improved glycemic control and treatment satisfaction among those using MiniMed™ 780G system¹, compared to insulin injections Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced results from the Medtronic ADAPT study were published in The...
First-of-its-kind study demonstrates individuals using the Medtronic system achieved 1.4% absolute reduction in A1c and 27.6% absolute increase in Time in Range DUBLIN , Sept. 1, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today ann
Read more →MDTMedtronic announces partnership with BioIntelliSense for exclusive U.S. distribution of multi-parameter wearable for continuous remote patient monitoring from in-hospital to home Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership with BioIntelliSense, ...
DUBLIN , Aug. 31, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it has entered into a strategic partnership with BioIntelliSense, a continuous health monitoring and clinical intelligence company, for the exclusive U.S.
Read more →MDTMedtronic completes acquisition of Affera Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Affera, Inc. This...
Acquisition adds mapping and navigation platform to company's cardiac ablation portfolio and brings an integrated system of diagnostic and therapeutic tools to address a broad spectrum of arrhythmias DUBLIN , Aug. 30, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global lea
Read more →MDTMedtronic Extravascular ICD meets global pivotal clinical trial's safety and effectiveness endpoints Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its investigational EV ICD™ System – a first-of-its-kind...
Late-breaking data presented at ESC Congress 2022 and simultaneously published in The New England Journal of Medicine confirms implant procedure safety and defibrillation success DUBLIN and BARCELONA, Spain , Aug. 28, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global lea
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports first quarter fiscal 2023 financial results Reven
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 Medtronic reports first quarter fiscal 2023 financial results Revenue exceeds guidance, with known supply chain challenges impacting results notable streng
Read more →MDTMedtronic reports first quarter fiscal 2023 financial results Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2023, which ended July 29, 2022. Key Highlights GAAP...
Revenue exceeds guidance, with known supply chain challenges impacting results; notable strength in Pacing, Cardiac Surgery, Core Spine in the U.S., and Diabetes in Europe DUBLIN , Aug. 23, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its
Read more →MDTMedtronic announces cash dividend for second quarter of fiscal year 2023 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 18, 2022, approved the fiscal year 2023 second quarter cash dividend of $0.68...
DUBLIN , Aug. 18, 2022 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT ) on Thursday, August 18, 2022 , approved the fiscal year 2023 second quarter cash dividend of $0.68 per ordinary share, representing an 8% increase over the prior year. This quarterly decla
Read more →MDTMedtronic to announce financial results for its first quarter of fiscal year 2023 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of...
DUBLIN , Aug. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2023 on Tuesday, August 23, 2022 . A news release will be issued at approximatel
Read more →MDTMedtronic expands Health Equity Assistance Program for colon cancer screening with support from Amazon Web Services; Completes first installation of donated GI Genius™ intelligent endoscopy modules Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and the American Society for Gastrointestinal Endoscopy (ASGE) today announced...
DUBLIN , July 15, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, and the American Society for Gastrointestinal Endoscopy (ASGE) today announced they are expanding the Medtronic Health Equity Assistance Program for colon cancer screening
Read more →MDTMedtronic receives FDA clearance for next-generation UNiD™ Spine Analyzer with degenerative spine surgery predictive model Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k)...
Powered by a database of over 10,000 surgical cases, Medtronic continues to evolve the UNiD™ platform to help surgeons plan procedures, personalize care for their patients and predict post-operative spinal compensation DUBLIN , July 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE:
Read more →MDTMedtronic announces co-promotion agreement with CathWorks, with path toward acquisition Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has entered into a strategic partnership agreement with...
DUBLIN and KEFAR SAVA, Israel , July 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it has entered into a strategic partnership agreement with CathWorks, a privately held company headquartered in Kefar Sava, Israel ,
Read more →MDTDocument CONTACTS Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Board appoints Lidia Fonseca as a new director DUBLIN
CONTACTS Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 Medtronic Board appoints Lidia Fonseca as a new director DUBLIN - June 27, 2022 - Medtronic plc (NYSE MDT) today announced that its Board of Directors appointed
Read more →MDTMedtronic Board appoints Lidia Fonseca as a new director Medtronic plc (NYSE: MDT) today announced that its Board of Directors appointed Lidia Fonseca, Executive Vice President, Chief Digital and Technology ...
DUBLIN , June 27, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced that its Board of Directors appointed Lidia Fonseca , Executive Vice President, Chief Digital and Technology Officer at Pfizer, to the Board as an independent director, effective June 27, 2022 . Ms.
Read more →MDTMedtronic chairman and CEO Geoff Martha to speak at Goldman Sachs global healthcare conference Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it will participate in the 43rd annual Goldman Sachs global...
DUBLIN , May 31, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it will participate in the 43rd annual Goldman Sachs global healthcare conference on Tuesday, June 14, 2022 . Geoff Martha , Medtronic chairman and chief e
Read more →MDT▼ -5.8%on this newsshared move
Medtronic reports full year and fourth quarter fiscal year 2022 financial results; announces 8% dividend increase Medtronic plc (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2022, which ended April 29, 2022. Key Highlights...
Mid-single digit FY22 revenue growth; Q4 results affected by temporary global supply chain impacts and China lockdowns DUBLIN , May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its fourth quarter and fiscal year 2022, which ended Apri
Read more →MDT▼ -5.8%on this newsshared move
Medtronic and DaVita announce new kidney health technology company Medtronic plc (NYSE:MDT) and DaVita Inc. (NYSE:DVA) today announced the intent to form a new, independent kidney care-focused medical device company...
Companies join forces to accelerate kidney care device innovation and improve patient outcomes DUBLIN and DENVER , May 26, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) and DaVita Inc. (NYSE: DVA ) today announced the intent to form a new, independent kidney care-focused medic
Read more →MDT▼ -5.8%on this newsshared move
Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports full year and fourth quarter fiscal year 2022 financial re
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 Medtronic reports full year and fourth quarter fiscal year 2022 financial results announces 8% dividend increase Mid-single digit FY22 revenue growth Q4 r
Read more →MDTMedtronic to announce financial results for its fourth quarter and full fiscal year 2022 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and...
DUBLIN , May 19, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 . A news release will be issued at approxim
Read more →MDTEuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure...
Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE DUBLIN and PARIS , May 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced data showing the benef
Read more →MDTMedtronic receives FDA approval for latest generation drug-eluting coronary stent system Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received U.S. Food and Drug Administration (FDA) approval for...
The Onyx Frontier™ drug-eluting stent offers an innovative delivery system and builds upon the acute performance and clinical data from the Resolute Onyx™ drug-eluting stent DUBLIN , May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technolog
Read more →MDTMedtronic completes acquisition of Intersect ENT Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it has completed the acquisition of Intersect ENT,...
Acquisition adds innovative bioabsorbable steroid-eluting sinus implants to ENT portfolio DUBLIN and MENLO PARK, Calif. , May 13, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that it has completed the acquisition of I
Read more →MDTMedtronic and GE Healthcare announce a collaboration to meet growing need for outpatient care Providing excellent care inside and outside of the traditional hospital is the new normal for patients, clinicians, and payers seeking more choices...
DUBLIN and CHICAGO , April 28, 2022 /PRNewswire/ -- Providing excellent care inside and outside of the traditional hospital is the new normal for patients, clinicians, and payers seeking more choices without compromising excellent outcomes. Today, Medtronic and GE Healthcare anno
Read more →MDTMedtronic names new chief scientific, medical, and regulatory officer Medtronic plc (NYSE:MDT) today announced that Laura Mauri, M.D., M.S.c. has been appointed Medtronic Chief Scientific, Medical and Regulatory Officer....
Dr. Laura Mauri will drive integration of medical and scientific intelligence and patient safety and engagement as chief scientific, medical and regulatory officer DUBLIN , April 25, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced that Laura Mauri , M.D., M.S.c.
Read more →MDTACC.22: Medtronic renal denervation system demonstrates significant blood pressure reduction through three years Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced long-term data from the first 80 patients in the SPYRAL HTN-ON...
DUBLIN and WASHINGTON , April 4, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which were presented today at the American College of Cardiology's
Read more →MDTMedtronic announces first patient implants of investigational implantable tibial neuromodulation therapy for bladder incontinence Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the first patient implants in the TITAN 2 pivotal study that...
TITAN 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy DUBLIN , March 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the first patient imp
Read more →MDTMedtronic survey finds pandemic creating far-reaching and negative impacts on those with chronic back or leg pain A new survey commissioned by Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and conducted by public opinion research firm The...
Medtronic and Harris Poll survey finds 4 in 5 report chronic back or leg pain is worse or unimproved since the COVID-19 pandemic began DUBLIN , March 23, 2022 /PRNewswire/ -- A new survey commissioned by Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, and c
Read more →MDTMedtronic appoints new Operating Unit Presidents Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units –...
DUBLIN , March 17, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced leadership transitions for three of its Operating Units – Diabetes, Surgical Robotics, and Cardiac Rhythm Management – bringing in critical skills and cap
Read more →MDTFirst U.S. trial using GI Genius™ intelligent endoscopy module shows 50% reduction in missed colorectal polyps with artificial intelligence (AI) technology versus standard colonoscopy Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, international, multi-center...
Findings published in Gastroenterology show that AI technology assisted coloscopy improves the accuracy of polyp detection, which plays an important role in the prevention of colorectal cancer DUBLIN , March 16, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in
Read more →MDTMedtronic announces contract with Vizient for Touch Surgery™ Enterprise Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has entered into a contract with Vizient, a leading...
The first AI-powered video management and analytics platform for the OR, Touch Surgery Enterprise gives surgical teams easy access to procedural videos and insights DUBLIN , March 9, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today
Read more →MDTMedtronic announces cash dividend for fourth quarter of fiscal year 2022 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, March 3, 2022, approved the fiscal year 2022 fourth quarter cash dividend of $0.63...
DUBLIN , March 4, 2022 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT ) on Thursday, March 3, 2022 , approved the fiscal year 2022 fourth quarter cash dividend of $0.63 per ordinary share, representing an 8.6 percent increase over the prior year. This quarterl
Read more →MDTMedtronic announces launch of NuVent™ Eustachian tube dilation balloon Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of the NuVent™ Eustachian tube dilation balloon,...
DUBLIN , Feb. 28, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the launch of the NuVent™ Eustachian tube dilation balloon, which has been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of chro
Read more →MDTMedtronic Executive Vice President and CFO to speak at Cowen healthcare conference Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate virtually in the 42nd annual Cowen...
DUBLIN , Feb. 28, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it will participate virtually in the 42nd annual Cowen healthcare conference on Monday, March 7, 2022 . Karen Parkhill , Medtronic executive vice presiden
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports third quarter fiscal 2022 financial results Compa
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 Medtronic reports third quarter fiscal 2022 financial results Company advanced its pipeline, launched new products, won share, and delivered earnings growt
Read more →MDTMedtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration...
DUBLIN , Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for InterStim X™ ― the next generation of the InterStim™ portfolio's recharge-free de
Read more →MDTMedtronic to provide underserved communities with artificial intelligence (AI)-assisted colonoscopy technology through Health Equity Assistance Program for colon cancer screening Medtronic plc (NYSE: MDT), a global leader in healthcare technology, and the American Society for Gastrointestinal Endoscopy (ASGE) today announced...
DUBLIN , Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, and the American Society for Gastrointestinal Endoscopy (ASGE) today announced they are working to provide colorectal cancer screening technologies in low income and under
Read more →MDTMedtronic reports third quarter fiscal 2022 financial results Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2022, which ended January 28, 2022. We're...
Company advanced its pipeline, launched new products, won share, and delivered earnings growth despite COVID-19 impact on healthcare procedure volumes DUBLIN , Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its third quarter of fis
Read more →MDTMedtronic receives FDA expanded approval for cardiac cryoablation catheters for pediatric treatment of a common heart rhythm condition Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation...
DUBLIN , Feb. 18, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that the Freezor™ and Freezor™ Xtra Cardiac Cryoablation Catheters are approved by the U.S. Food and Drug Administration (FDA) and are the only ablation ca
Read more →MDTMedtronic to announce financial results for its third quarter of fiscal year 2022 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of...
DUBLIN , Feb. 8, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2022 on Tuesday, February 22, 2022 . A news release will be issued at approximate
Read more →MDTMedtronic announces first procedure in Europe with Hugo™ robotic-assisted surgery system Medtronic plc (NYSE:MDT), a global leader in healthcare technology, and OLV Hospital Aalst today announced that the first clinical procedure in...
Robotic prostatectomy performed by Doctor Alexandre Mottrie at Onze-Lieve-Vrouw Ziekenhuis (OLV) in Aalst, Belgium DUBLIN and AALST, Belgium , Feb. 2, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, and OLV Hospital Aalst today announce
Read more →MDTMedtronic announces FDA approval of spinal cord stimulation therapy for treating chronic pain resulting from diabetic peripheral neuropathy Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval of its ...
DUBLIN , Jan. 24, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it has received U.S. Food and Drug Administration approval of its Intellis™ rechargeable neurostimulator and Vanta™ recharge-free neurostimulator for the t
Read more →MDTMedtronic Foundation launches new STEM partnerships to serve over 60,000 underserved and underrepresented students The Medtronic Foundation today announced 13 new partnerships with leading organizations serving underrepresented and underserved K-12 students in...
DUBLIN and MINNEAPOLIS , Jan. 21, 2022 /PRNewswire/ -- The Medtronic Foundation today announced 13 new partnerships with leading organizations serving underrepresented and underserved K-12 students in Minnesota , Northern California and Puerto Rico . Partnerships will address the
Read more →MDTMedtronic announces results showing meaningful pain relief using DTM™ Spinal Cord Stimulation endurance therapy Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced three-month results from an on-label, prospective, multi-center...
DTM™ SCS endurance therapy enables long-lasting recharge-free performance on Vanta™ and 5-minute recharge on Intellis™ neurostimulators DUBLIN , Jan. 14, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced three-month result
Read more →MDTMedtronic announces schedule for presentations at the 2022 North American Neuromodulation Society Meeting Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its schedule for presentations at the 25th Annual North American...
Sessions will include DTM™ SCS endurance therapy 3-month outcomes for patients with chronic back and leg pain DUBLIN , Jan. 12, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced its schedule for presentations at the 25th A
Read more →MDTMedtronic announces regulatory approval and launch in Japan of Micra AV Transcatheter Pacing System Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has received approval from Japan's Ministry of Health, Labor...
DUBLIN , Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it has received approval from Japan's Ministry of Health, Labor and Welfare for the sale and reimbursement of the Micra™ AV Transcatheter Pacing System (TP
Read more →MDTMedtronic Announces Approval of the Evolut™ PRO TAVR System in China Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has approved...
First Medtronic TAVR system approved in China for patients with symptomatic severe aortic stenosis DUBLIN , Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the National Medical Products Administration (NMPA) has
Read more →MDTMedtronic to Acquire Affera Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it has entered into a definitive agreement to acquire...
Acquisition to expand company's cardiac ablation portfolio, including first-time entry into mapping and navigation, within one of the fastest growing medtech markets DUBLIN , Jan. 10, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, toda
Read more →MDTMedtronic Chairman and CEO Geoff Martha to speak at J.P. Morgan healthcare conference Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate virtually in the 40th annual J.P. Morgan...
DUBLIN , Jan. 4, 2022 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced it will participate virtually in the 40th annual J.P. Morgan healthcare conference on Monday, January 10, 2022 . Geoff Martha , Medtronic chairman and chie
Read more →MDTCMS expands diabetes Medicare coverage to include CGMs that integrate with Medtronic insulin pumps Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will ...
DUBLIN , Dec. 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) will expand Medicare coverage for all types of continuous glucose monitors (CGMs), including a
Read more →MDTMedtronic announces two executive committee changes Medtronic plc (NYSE:MDT), a global leader in healthcare technology, made two announcements today regarding its executive committee. Ivan Fong has...
DUBLIN , Dec. 16, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, made two announcements today regarding its executive committee. Ivan Fong has been named as general counsel and secretary, succeeding Brad Lerman , who will retire at the
Read more →MDT▼ -6%on this newsshared move
Medtronic Diabetes receives FDA warning letter Medtronic plc (NYSE:MDT) today announced it received a warning letter from the U.S. Food and Drug Administration (FDA) on December 9 for the...
DUBLIN , Dec. 15, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced it received a warning letter from the U.S. Food and Drug Administration (FDA) on December 9 for the company's Northridge, California , facility, the headquarters for its Diabetes Business . The warn
Read more →MDT▼ -6%on this newsshared move
Document NEWS RELEASE Contacts Pamela Reese Ryan Weispfenning Public Relations Investor Relations +1-818-576-3398 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Diabetes receives FDA warning letter DUBLIN
EX-99.1 2 exhibit991-pressrelease121.htm EX-99.1 Document NEWS RELEASE Contacts Pamela Reese Ryan Weispfenning Public Relations Investor Relations +1-818-576-3398 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Diabetes receives FDA warning letter DUBLIN December 15, 2021 Medtron
Read more →MDTMedtronic INVOS™ 7100 Cerebral/Somatic Oximetry System receives 510(k) clearance for pediatric indications Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted...
FDA clearance expands use of the INVOS™ 7100 system, helping clinicians better monitor organ-specific oxygen levels and identify warnings signs for neonates and children earlier "Timing is critical for vulnerable pediatric patients, and the INVOS™ 7100 system can alert clinician
Read more →MDTNew study finds procedures treating spinal fractures associated with reduction in opioid use and decreased payer costs Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International...
DUBLIN , Dec. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced the results of a study published in Osteoporosis International that demonstrate a decrease, and in some cases elimination of oral opioids, and decrease in
Read more →MDTMedtronic announces cash dividend for third quarter of fiscal year 2022 The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 9, 2021, approved the fiscal year 2022 third quarter cash dividend of $0.63...
DUBLIN , Dec. 10, 2021 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT ) on Thursday, December 9, 2021 , approved the fiscal year 2022 third quarter cash dividend of $0.63 per ordinary share, representing a 9 percent increase over the prior year. This quarterly
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic reports second quarter fiscal 2022 financial results Comp
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 Medtronic reports second quarter fiscal 2022 financial results Company continued to launch new products, win share, and deliver strong earnings growth mark
Read more →MDTMedtronic Reports Second Quarter Fiscal 2022 Financial Results Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021. Key Highlights...
DUBLIN , Nov. 23, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021 . "As our markets recover, Medtronic is one of the best positioned companies in healthcare." Chairman & CE
Read more →MDTMedtronic announces 510(k) clearance for PillCam™ Small Bowel 3 @HOME endoscopy procedure Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted...
DUBLIN , Nov. 15, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its PillCam™ Small Bowel 3 system for remote endoscopy procedures. The Pi
Read more →MDTMedtronic taps top digital and healthcare technology leaders to drive company transformation Medtronic plc (NYSE:MDT) today announced four executive appointments to further its commitment to become the global leader in healthcare technology....
Four external appointments include new digital innovation leader, head of global strategy and two Operating Unit President roles within the Neuroscience Portfolio DUBLIN , Nov. 15, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced four executive appointments to fur
Read more →MDTMedtronic named to the Dow Jones Sustainability World Index Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its inclusion in the Dow Jones® Sustainability World Index (DJSI...
DUBLIN , Nov. 15, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced its inclusion in the Dow Jones® Sustainability World Index (DJSI World) as one of the world's leading companies for sustainability. The DJSI World Index in
Read more →MDTMedtronic to announce financial results for its second quarter of fiscal year 2022 Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of...
DUBLIN , Nov. 9, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced that it will report financial results for its second quarter of fiscal year 2022 on Tuesday, November 23, 2021 . A news release will be issued at approximat
Read more →MDTMedtronic announces 2045 net zero emissions ambition to combat climate change Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced its ambition to achieve net zero carbon emissions by fiscal year...
DUBLIN , Nov. 8, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced its ambition to achieve net zero carbon emissions by fiscal year (FY) 2045 across its operations and value chain (scopes 1, 2, and 3) to accelerate efforts
Read more →MDTMedtronic announces early data for the Intrepid™ transcatheter mitral valve replacement (TMVR) system using new transfemoral delivery system Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today presented early data for its self-expanding Intrepid™ transcatheter mitral...
Transfemoral access added into landmark APOLLO Pivotal Trial following IDE approval from FDA DUBLIN and ORLANDO, Fla. , Nov. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today presented early data for its self-expanding Intrepid ™
Read more →MDTMedtronic self-expanding TAVR platform shows excellent longer-term performance at five years in SURTAVI Trial Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today unveiled five-year clinical data from the Surgical Replacement and...
TCT 2021: Intermediate risk TAVR patients demonstrate strong hemodynamics and stable valve performance at five years DUBLIN and ORLANDO, Fla. , Nov. 5, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today unveiled five-year clinical da
Read more →MDTMedtronic study shows patients with high blood pressure are interested in an interventional procedure treatment option Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced findings from a new study of the Patient Preferences for the...
New data from Medtronic Patient Preference study presented at TCT 2021; Medtronic adds to its clinical leadership for renal denervation with launch of the SPYRAL AFFIRM study DUBLIN and ORLANDO, Fla. , Nov. 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in h
Read more →MDTAustin L. Chiang, M.D., M.P.H. joins Medtronic as Chief Medical Officer for Gastrointestinal business Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced Austin L. Chiang, M.D., M.P.H., assistant professor of medicine...
DUBLIN , Oct. 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in healthcare technology, today announced Austin L. Chiang , M.D., M.P.H., assistant professor of medicine at Sidney Kimmel Medical College, chief medical social media officer of Jefferson Health a
Read more →MDTChildren achieve Time in Range mirroring well-controlled adults for the first time in real-world study of the MiniMed™ 780G system Medtronic plc (NYSE: MDT), a leading global healthcare technology company, recently announced one-year, real-world clinical data on 3,211 pediatric...
Harder to manage pediatric and adolescent patients achieve 74% Time in Range, and 82% overnight Time in Range, well surpassing clinical consensus guidelines for glycemic control DUBLIN , Oct. 19, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a leading global healthcare techno
Read more →MDTMedtronic announces new ESG targets in its FY21 Integrated Performance Report and unveils refreshed brand Medtronic plc (NYSE:MDT) today released its fiscal year (FY) 2021 Integrated Performance Report: Engineering Impact and will share key updates at its ...
Company to highlight environmental, social, and governance (ESG) efforts in inaugural ESG Investor Briefing DUBLIN , Oct. 12, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today released its fiscal year (FY) 2021 Integrated Performance Report: Engineering Impact and will share
Read more →MDTMedtronic Hugo™ Robotic-Assisted Surgery System Receives European CE Mark Approval Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the Hugo™...
Multiple Hospitals Across Europe Set to be the First to Install Hugo™ RAS System and Expand the Benefits of Robotic-Assisted Surgery to Their Patients DUBLIN , Oct. 11, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it h
Read more →MDTContinuous Rhythm Monitoring Reveals Strong Short-Term Risk Association Between Atrial Fibrilation Episodes and Ischemic Stroke Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the publication of a study demonstrating, through the use of a...
DUBLIN , Oct. 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the publication of a study demonstrating, through the use of a Medtronic continuous rhythm monitoring device, that atrial fibrillation (AF) is directly and t
Read more →MDTMedtronic Expands Minimally Invasive Spine Surgery Ecosystem with Next-Generation Spinal Technologies Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery...
DUBLIN , Sept. 30, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robot
Read more →MDTMedtronic Receives CE Mark Approval for Radial Artery Access Portfolio Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE Mark approval for its radial artery access...
DUBLIN , Sept. 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received CE Mark approval for its radial artery access portfolio, which includes the Rist™ 079 Radial Access Guide Catheter and Rist™ Radial Access
Read more →MDTFirst Procedure in Asia-Pacific Performed with Medtronic Hugo™ Robotic-Assisted Surgery System Medtronic plc (NYSE:MDT) and Apollo Hospitals Group today announced the first clinical procedure in Asia-Pacific with the Hugo™ robotic-assisted...
The Robotic Prostatectomy Took Place at Apollo Hospitals, Greams Road, Chennai, India DUBLIN and CHENNAI, India , Sept. 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) and Apollo Hospitals Group today announced the first clinical procedure in Asia-Pacific with the Hugo™ robo
Read more →MDTU.S. Patent Office Completes Review of Medtronic Patents, Rejects More Axonics Challenges Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and...
All Medtronic patents affirmed by the PTAB have been in force for every sale Axonics has made to-date. "Medtronic appreciates the Patent Trial and Appeal Board's efforts in this matter," said Brett Wall , executive vice president and president of the Neuroscience Portfolio at Me
Read more →MDTMedtronic Begins Pediatric Clinical Trial of Spinal Tether for Treatment of Scoliosis Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that it has enrolled its first patient and completed the first...
As First Patient Is Enrolled in the Clinical Trial of Braive™ Growth Modulation System, Study Reaffirms Medtronic's Commitment to Pediatric Spine Innovation DUBLIN , Sept. 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announc
Read more →MDTU.S. Patent and Trademark Office Rejects Axonics' Challenge to Medtronic Patents Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has won three additional important victories in a dispute over...
DUBLIN , Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has won three additional important victories in a dispute over its intellectual property (IP) for its sacral neuromodulation device family, the InterSti
Read more →MDTMedtronic Collaboration with Mpirik to Address Disparities in Care Associated with Sudden Cardiac Arrest Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care...
DUBLIN , Sept. 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced a pilot program with Mpirik to address disparities in care associated with the prevention of sudden cardiac arrest (SCA), a condition in which the heart su
Read more →MDTMedtronic Executives to Speak at Upcoming Investor Conferences Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor...
DUBLIN , Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it will participate virtually in the following upcoming investor conferences: 2021 Virtual Wells Fargo Healthcare Conference Thursday, September 9, 2021 ,
Read more →MDTMedtronic Announces NAVABLATE Study Results Released in Late-Breaking Podium Presentation at European Respiratory Society International Congress 2021 Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the NAVABLATE study, which highlights the...
Results Demonstrate Feasibility of Bronchoscopic Microwave Ablation for Certain Patients with Malignant Lung Nodules DUBLIN , Sept. 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced new clinical data from the NAVABLATE s
Read more →MDTReal-World Data Demonstrate Significant Reduction in Complications and Reinterventions with Medtronic Micra Leadless Pacemaker Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new data from the Micra Coverage with Evidence Development (CED)...
Results Presented at ESC 2021 Show Micra TPS Compares Favorably to Traditional Pacemakers DUBLIN , Aug. 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced new data from the Micra Coverage with Evidence Development (CED)
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS Stron
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS Strong Financial Performance on Continued Procedure Volume Recovery and Share Gains from New
Read more →MDTMedtronic Reports First Quarter Fiscal 2022 Financial Results Medtronic plc (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021. Key Highlights...
DUBLIN , Aug. 24, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its first quarter of fiscal year 2022, which ended July 30, 2021 . "FY22 is off to a strong start - Q1 reflects solid execution and continued procedure recovery." - Chairman &
Read more →MDTMedtronic Announces FDA Approval of Next-Gen TAVR System for Treatment of Symptomatic Severe Aortic Stenosis Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) approval of its...
The Evolut FX system incorporates the same supra-annular valve design that has shown hemodynamic performance superior to surgical aortic valve replacement (SAVR) across large-scale, randomized clinical trials. The fourth-generation Evolut technology is equipped with gold markers
Read more →MDTMedtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2022 The board of directors of Medtronic plc (NYSE: MDT) on Friday, August 20, 2021, approved the fiscal year 2022 second quarter cash dividend of $0.63...
DUBLIN , Aug. 23, 2021 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT ) on Friday, August 20, 2021 , approved the fiscal year 2022 second quarter cash dividend of $0.63 per ordinary share, representing a 9 percent increase over the prior year. This quarterly d
Read more →MDTMedtronic to Announce Financial Results for its First Quarter of Fiscal Year 2022 Medtronic plc (NYSE:MDT) announced today that it will report financial results for its first quarter of fiscal year 2022 on Tuesday, August 24, 2021. ...
DUBLIN , Aug. 10, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) announced today that it will report financial results for its first quarter of fiscal year 2022 on Tuesday, August 24, 2021 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and
Read more →MDTMedtronic to Acquire Intersect ENT Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT ...
DUBLIN and MENLO PARK, Calif. , Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT ), a global ear, nose, and throat (ENT) medical techn
Read more →MDTFirst Gynecological Procedures Performed with Medtronic Hugo™ Robotic-Assisted Surgery System Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first gynecological (GYN) procedures with the Hugo™...
DUBLIN , July 29, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the first gynecological (GYN) procedures with the Hugo™ robotic-assisted surgery (RAS) system. The six cases included hysterectomies and myomectomies perfor
Read more →MDTMedtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance for two...
AI Algorithms Enhance LINQ II™ Insertable Cardiac Monitor Diagnostic Accuracy for Improved Management of Patients DUBLIN , July 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) c
Read more →MDTMedtronic TYRX™ Absorbable Antibacterial Envelope Is Effective at Reducing Infections in Cardiac Device Patients with Hematomas Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from the landmark WRAP-IT study published in Heart...
DUBLIN , July 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced new data from the landmark WRAP-IT study published in Heart Rhythm , demonstrating a significantly lower infection risk for patients who develop hematomas a
Read more →MDTMedtronic Launches Newest-Generation Drug Coated Balloon Catheter in Europe for Treatment of Coronary Artery Disease Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the launch of the Prevail™ drug coated balloon (DCB) Catheter in...
Medtronic Prevail DCB™ Designed to Treat Complex Lesions with Superior Deliverability, Rapid Absorption of Paclitaxel DUBLIN , July 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the launch of the Prevail™ drug coate
Read more →MDTMedtronic Hugo™ Robotic-Assisted Surgery System Cornerstone of New Robotics Program in Latin America Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the integration of the Hugo™ robotic-assisted surgery (RAS) system ...
Advanced Technology at UC CHRISTUS Expands Access to Minimally Invasive Surgery for More Patients DUBLIN , July 20, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the integration of the Hugo™ robotic-assisted surgery (RA
Read more →MDTEconomic Analysis Finds Continuous Monitoring for Respiratory Depression May Provide Benefits to Patients and Reduce Hospital Costs Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of an economic model based on data from the...
Economic Model Based on PRODIGY Trial Data Demonstrates Continuous Pulse Oximetry and Capnography Monitoring of High-Risk Patients May Reduce Hospital Costs by Over $500,000 Annually DUBLIN , July 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical t
Read more →MDTMedtronic Launches App-Based Study to Better Understand Relationship Between Atrial Fibrillation Disease Burden and Impact on Patient Outcomes Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the initiation of the DEFINE AFib study, the company's first...
DEFINE AFib Study Will Leverage Data from Medtronic Insertable Cardiac Monitors and Medtronic Discovery App™ with the Goal of Informing Atrial Fibrillation (AF) Management Strategies DUBLIN , June 29, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical
Read more →MDTMedtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced key clinical data from the virtual 81st annual American Diabetes...
Data Were Presented at the American Diabetes Association 81 st Scientific Sessions DUBLIN , June 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced key clinical data from the virtual 81 st annual American Diabetes Associ
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ANNO
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2021 FINANCIAL RESULTS ANNOUNCES 9% DIVIDEND INCREASE Q4 Revenue of $8.2 Billion Increased 37% Reported and
Read more →MDTMedtronic Announces Real-World Data on InPen™ and Extended Infusion Set* Pivotal Trial Data at the American Diabetes Association 81st Scientific Sessions Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced its participation at the American Diabetes Association (ADA) 81th ...
DUBLIN , June 23, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced its participation at the American Diabetes Association (ADA) 81 th scientific sessions virtual meeting, June 25-29, 2021 . Medtronic will be participating i
Read more →MDTFirst Procedure in the World with Medtronic Hugo™ Robotic-Assisted Surgery System Performed at Clínica Santa Maria in Chile Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient procedure with the Hugo™ robotic-assisted...
The Robotic Prostatectomy Marked the Start of the Hugo™ RAS System Global Patient Registry DUBLIN , June 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the first patient procedure with the Hugo™ robotic-assisted surg
Read more →MDTMedtronic Receives FDA Expanded Approval for Arctic Front™ Family of Cardiac Cryoablation Catheters for Initial Use for Recurrent Symptomatic Paroxysmal Atrial Fibrillation Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it received U.S. Food and Drug Administration (FDA) expanded...
- First and Only Approval to Indicate Cryoablation as an Initial Rhythm Control Strategy - Offers Safe, Effective Alternative to Antiarrhythmic Drug Therapy for the Prevention of Atrial Arrythmia Recurrence DUBLIN , June 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the
Read more →MDTMedtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval...
DUBLIN , June 10, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a devic
Read more →MDTMedtronic Insertable Cardiac Monitor Detects Significantly Higher Rates of Atrial Fibrillation in Large and Small Vessel Stroke Patients Compared to Standard of Care Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results from the STROKE AF trial demonstrating the...
DUBLIN , June 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced clinical trial results from the STROKE AF trial demonstrating the superiority of the Reveal LINQ™ Insertable Cardiac Monitor (ICM) to detect abnormal heartbe
Read more →MDTFDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and first U.S....
DUBLIN , June 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead System used for Deep Brain Stimulation (DBS) t
Read more →MDTMedtronic Gains FDA Clearance of UNiD™ Patient-Specific Rods for Use with CD Horizon™ Solera™ Voyager™ and Infinity™ OCT Spinal Systems Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) clearance of...
DUBLIN , June 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) clearance of patient-specific UNiD™ Rods for use with Medtronic CD Horizon™ Solera™ Voyager™ and Infinity™ OCT sp
Read more →MDTMedtronic to Stop Distribution and Sale of HVAD™ System Medtronic plc (NYSE:MDT), the global leader in medical technology, is stopping the distribution and sale of the Medtronic HVAD™ System. This morning, ...
- Company Developing Support Program for Current HVAD Patients - Medtronic Coordinating with Global Regulators to Assure Patient Access to Left Ventricular Assist Devices DUBLIN , June 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology,
Read more →MDTReal-World Data on Over 4,000 Patients Using the Medtronic MiniMed™ 780G System Demonstrate Time in Range Mirroring Pivotal Trial Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the MiniMed™ ...
Results Demonstrate 76% Time in Range and 94% Time in Advanced Hybrid Closed Loop Mode DUBLIN , June 2, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced real-world clinical outcomes for 4,120 individuals on the MiniMed™ 78
Read more →MDTMedtronic Announces Scientific Data Presentations at the 14th International Conference on Advanced Technologies & Treatments for Diabetes Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its virtual participation at the 14th International Conference on...
Data on the Company's Holistic Portfolio Will Include Real-World Data on MiniMed™ 780G System and New Data on Medtronic Continuous Glucose Monitoring Systems and Extended-Wear Infusion Set DUBLIN , June 1, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in med
Read more →MDTMedtronic Reports Fourth Quarter and Fiscal Year 2021 Financial Results; Announces 9% Dividend Increase Medtronic plc (NYSE:MDT) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021. The company...
DUBLIN , May 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its fourth quarter and fiscal year 2021, which ended April 30, 2021 . The company reported fourth quarter worldwide revenue of $8.188 billion , an increase of 37 percent as repo
Read more →MDTMedtronic Secures Two CE Mark Approvals for Guardian 4 Sensor & for InPen MDI Smart Insulin Pen Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark for expanded functionality of the...
New No Fingerstick 1 Sensor Integrates with Both the MiniMed 780G System and the Smart InPen System "We look forward to having multiple ways to help our patients manage their diabetes as we know that patient needs and preferences can vary greatly," said Prof. Goran Petrovski , M
Read more →MDTMedtronic Evolut™ TAVR System Shows Strong Performance at Two Years in Low Risk Trial Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk...
DUBLIN , May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the complete two-year outcomes from the landmark Evolut Low Risk Trial comparing the minimally invasive Evolut™ transcatheter aortic valve replacement (TAVR)
Read more →MDTLate Breaking Data at EuroPCR Demonstrates Long-Term Benefits of Medtronic Radiofrequency Renal Denervation in Real-World Hypertensive Patients Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new clinical data from the Global SYMPLICITY Registry (GSR)...
Medtronic Launches New GSR-DEFINE Study to Expand Real-World Data to 5,000 Patients DUBLIN , May 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced new clinical data from the Global SYMPLICITY Registry (GSR) indicating t
Read more →MDTNew Survey Identifies Opportunity to Improve Shared Decision Making Between Cardiologists and Heart Valve Disease Patients New findings from an American College of Cardiology's (ACC) survey revealed more than half of cardiologists (57%) believe patient preparation may...
More than five million Americans are currently impacted by heart valve disease, and 1.5 million have one of the most common forms, aortic stenosis (AS). Currently, treatment options for AS include transcatheter aortic valve replacement (TAVR), a minimally invasive procedure, or a
Read more →MDTMedtronic to Announce Financial Results for its Fourth Quarter and Full Fiscal Year 2021 Medtronic plc (NYSE:MDT) announced today that it will report financial results for its fourth quarter and full fiscal year 2021 on Thursday, May 27,...
DUBLIN , May 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) announced today that it will report financial results for its fourth quarter and full fiscal year 2021 on Thursday, May 27, 2021 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT)
Read more →MDTMedtronic and Medtronic Foundation Partner to Address COVID-19 Surges with Focus on Equity Medtronic plc (NYSE:MDT) and the Medtronic Foundation announced an additional $3M USD for COVID-19 relief efforts – a combination of financial...
DUBLIN and MINNEAPOLIS , May 13, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) and the Medtronic Foundation announced an additional $3M USD for COVID-19 relief efforts – a combination of financial resources, personal protective equipment (PPE) donations, and Medtronic employee
Read more →MDTMedtronic Launches New Pediatric Monitor That Alerts Clinicians To Potential Airway Obstructions During Ventilation Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. commercial launch of the SonarMed™ airway monitoring...
Globally, 415,000 neonates and infants require invasive mechanical ventilation per year and are intubated for greater than 24 hours. Despite recommendations and reduction efforts, 75,000, or about one in five, of these neonates and infants will experience at least one unplanned e
Read more →MDTMedtronic Announces CareGuidePro™, a New Mobile App and Online Platform for Patients to Navigate Their Spinal Cord Stimulation Journey Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as...
DUBLIN , May 5, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced CareGuidePro™, a mobile application and web portal that serves as a virtual guide for patients throughout their Medtronic spinal cord stimulation therapy jour
Read more →MDTMedtronic Announces CE Mark of Evolut™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark of the Evolut™ PRO+ TAVI System – ...
As TAVI Patient Population Grows, PRO+ TAVI System Launches with Four Valve Sizes and Lowest Delivery Profile DUBLIN , May 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced CE (Conformité Européenne) Mark of the Evolut™
Read more →MDTProcedure-Related Techniques and Care Pathways from the OPTIMIZE PRO Clinical Study Show Promising Early Outcomes for Patients Implanted with the Medtronic Evolut™ TAVR System Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced results from an interim analysis of the first 171 patients...
DUBLIN , April 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced results from an interim analysis of the first 171 patients (including 71 roll-ins) treated in the OPTIMIZE PRO clinical study. The post-market, prospective
Read more →MDTMedtronic Receives FDA Breakthrough Designation for the Emprint™ Ablation Catheter Kit Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received Breakthrough Device Designation status from the...
Minimally Invasive Option Has Potential to Provide Long-Term Management of Lung Malignancies While Protecting Lung Function DUBLIN , April 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received Breakthrough D
Read more →MDTMedtronic Receives FDA Approval to Launch Clinical Study for Implantable Tibial Neuromodulation Therapy for Bladder Incontinence Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to...
DUBLIN , April 27, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced approval from the U.S. Food and Drug Administration (FDA) to proceed with an investigational device exemption (IDE) trial to evaluate its internally develo
Read more →MDTMedtronic Partners with Surgical Theater to Provide First Augmented Reality Platform for Use in Real-Time During Complex Cranial Procedures Medtronic plc (NYSE:MDT), the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater's ...
DUBLIN and LOS ANGELES , April 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, and Surgical Theater today announced a partnership to interface Surgical Theater's Sync AR ™ augmented reality (AR) technology with Medtronic's StealthStat
Read more →MDTMedtronic Receives U.S. FDA Approval for Pipeline™ Flex Embolization Device with Shield Technology™ Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug...
First Patient Receives New Shield Surface Modification, An Advance in Flow Diversion Therapy, at NYU Langone Health DUBLIN , April 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received approval from the Unit
Read more →MDTIN.PACT™ AV Drug-Coated Balloon Is First and Only to Show Superior and Sustained Results Through Two Years Compared to PTA in Treating Arteriovenous Fistulae Lesions Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the safety and effectiveness results through 24 months for the...
IN.PACT AV Access Trial 24 Month Results Presented as a Podium First at Charing Cross Symposium DUBLIN and LONDON , April 20, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the safety and effectiveness results through 24
Read more →MDTMedtronic Announces European Launch of World's First Infusion Set with Wear up to Seven Days to Help Reduce Burden for People with Diabetes Medtronic plc (NYSE: MDT), the global leader in medical technology, today introduced in select European countries the Medtronic Extended infusion set ...
DUBLIN , April 14, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today introduced in select European countries the Medtronic Extended infusion set — the first and only infusion set that can be worn for up to 7 days. An infusion set is t
Read more →MDTU.S. FDA Grants De Novo Clearance for First and Only Artificial Intelligence System for Colonoscopy; Medtronic Launches GI Genius™ Intelligent Endoscopy Module Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) granted de novo...
- The GI Genius ™ Module Assists Physicians in Detecting Pre-Cancerous Growths; Potentially Addressing 19 Million Colonoscopies Annually - Transformative AI Colorectal Cancer Prevention Platform Expands Medtronic Capabilities in Medical Technology Data Analytics and Insights DU
Read more →MDTMedtronic Announces Ongoing Initiatives to Address Health Equity for People of Color Living with Diabetes Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living ...
MINNEAPOLIS , April 7, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced its ongoing commitment to health equity for people of color living with diabetes. The company committed investments in partnerships with the American D
Read more →MDTThe Medtronic Foundation and Children's Heartlink Focus New Partnership on Health Equity for 10,000 Children and 10,000 Health Workers in Underserved Countries As the World Health Organization spearheads a global campaign on equity this World Health Day, the Medtronic Foundation and Children's HeartLink...
DUBLIN and MINNEAPOLIS , April 7, 2021 /PRNewswire/ -- As the World Health Organization spearheads a global campaign on equity this World Health Day, the Medtronic Foundation and Children's HeartLink (CHL) are announcing a $2.5 million , three-year, outcomes-based partnership to
Read more →MDTMedtronic Receives FDA Approval for Breakthrough Transcatheter Pulmonary Valve Replacement for Patients with Congenital Heart Disease Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval...
DUBLIN , March 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for its Harmony™ Transcatheter Pulmonary Valve (TPV), the first minimally invasive therapy
Read more →MDTMedtronic Receives CE Mark Approval for SenSight™ Directional Lead System for DBS Therapy Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the CE (Conformité Européenne) Mark for the SenSight™ directional...
This First-of-its-Kind Directional Lead Combines the Benefits of Directionality with the Power of Sensing DUBLIN , March 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the CE (Conformité Européenne) Mark for the SenS
Read more →MDTMedtronic Receives Approval for U.S. Labeling of the Intellis™ Platform Showing Superior Back Pain Relief When Using DTM™ Spinal Cord Stimulation Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised...
DUBLIN , March 17, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the U.S. Food and Drug Administration (FDA) has approved revised commercial labeling for the Intellis™ Platform with Differential Target Multiplexed (DTM™)
Read more →MDTMedtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2021 The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021, approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ...
DUBLIN , March 8, 2021 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT ) on Friday, March 5, 2021 , approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent increase over the prior year. This quarterly d
Read more →MDTMedtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption...
Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms DUBLIN , March 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the first procedures in the investigatio
Read more →MDTNew Analysis of REVERSE Trial Reveals Benefits of CRT for More Patients with Heart Failure Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes...
DUBLIN , March 2, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac resynchronization therapy (CRT) for patients with mild heart failure (HF). This
Read more →MDTMedtronic Reports Third Quarter Fiscal 2021 Financial Results Medtronic plc (NYSE:MDT) today announced financial results for its third quarter of fiscal year 2021, which ended January 29, 2021. The company...
- Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically - Q3 GAAP Diluted EPS of $0.94 ; Q3 Non-GAAP Diluted EPS of $1.29 DUBLIN , Feb. 23, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its third quarter of
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS Q3 Re
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS THIRD QUARTER FISCAL 2021 FINANCIAL RESULTS Q3 Revenue of $7.8 Billion Increased 0.8% as Reported and Decreased 1.0% Organically Q3 GAAP
Read more →MDTMedtronic Receives FDA Approval for Expanded MRI Labeling of InterStim™ SureScan™ MRI Leads Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received approval from the United States Food and Drug...
DUBLIN , Feb. 18, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received approval from the United States Food and Drug Administration (FDA) for expanded MRI labeling of its InterStim™ II and InterStim™ Micro sacra
Read more →MDTMedtronic Announces Voluntary Recall of Unused Valiant Navion™ Thoracic Stent Graft System Medtronic plc (NYSE:MDT), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™...
DUBLIN , Feb. 17, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, has voluntarily issued a global recall of unused Medtronic Valiant Navion™ thoracic stent graft system and informed physicians to immediately cease use of the device until
Read more →MDTMedtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2021 Medtronic plc (NYSE:MDT) announced today that it will report financial results for its third quarter of fiscal year 2021 on Tuesday, February 23,...
DUBLIN , Feb. 16, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) announced today that it will report financial results for its third quarter of fiscal year 2021 on Tuesday, February 23, 2021 . A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) a
Read more →MDTSurgeons Complete First Procedures Across the U.S. Utilizing Medtronic's Midas Rex™ Drills and Navigated Disc Prep and Interbodies with the Mazor™ Robotic Guidance System Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that leading spine surgeons across the U.S. have successfully...
Dr. Gregory Poulter of OrthoIndy , Dr. Sharad Rajpal of Boulder Neurosurgical & Spine Associates and Dr. Eiman Shafa of Twin Cities Spine Center Are First in the U.S. to Complete Surgeries Using the Most Comprehensive Integrated Spine Surgery Platform Available These cases demon
Read more →MDTNew Study in Newborns Finds Nellcor™ Pulse Oximetry Technology Provides Faster Stable Oxygen Saturation Readings Than Masimo Pulse Oximeter Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the results of an independent, prospective observational study...
- Study Compared the Efficacy and Reliability of Medtronic and Masimo Pulse Oximeters with Electrocardiography (ECG) Monitoring for Newborns - Nellcor™ Pulse Oximetry Technology Demonstrated Statistically Significant Difference in Time to Deliver a Stable Oxygen Saturation Value
Read more →MDTMedtronic Announces Early Site Release of New Radial Artery Access Portfolio Following First-in-Patient Procedure Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced expansion of its limited site release of the recently acquired...
Acquisition of RIST Neurovascular Enhances Medtronic's Capabilities to Serve Patients Treated for Brain Aneurysms and Other Neurovascular Conditions DUBLIN , Feb. 1, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced expansi
Read more →MDTMedtronic Recognized as One of Fortune's 2021 World's Most Admired Companies Medtronic plc (NYSE:MDT) has been named to FORTUNE's 2021 World's Most Admired Companies List. The global leader in medical technology landed at #4...
Global Leader in Medical Technology Ranks #4 in Industry on Annual List DUBLIN , Feb. 1, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) has been named to FORTUNE's 2021 World's Most Admired Companies List. The global leader in medical technology landed at #4 in the Medical Prod
Read more →MDTMedtronic Receives FDA Approval of DiamondTemp Ablation System for the Treatment of Patients with Atrial Fibrillation Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval...
DUBLIN , Jan. 29, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of the DiamondTemp™ Ablation (DTA) system which treats patients with recurrent, symptomatic
Read more →MDTMedtronic Launches First-of-Its-Kind Adaptive Deep Brain Stimulation (aDBS) Trial in Parkinson's Disease Patients Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first enrollment in ADAPT-PD (Adaptive DBS Algorithm for...
ADAPT-PD Global Study Designed to Demonstrate Safety & Efficacy of Automated Therapy Which Responds to Brain Signals in Parkinson's Disease Patients DUBLIN , Jan. 14, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the fi
Read more →MDTMedtronic Chairman and CEO Geoff Martha to Speak at J.P. Morgan Healthcare Conference Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the 39th Annual J.P. Morgan...
DUBLIN , Jan. 4, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 . Geoff Martha , Medtronic chairman and chief
Read more →MDTMedtronic Strengthens Leadership in Navigated, Robotic Spine Surgery with FDA Clearance of Midas Rex™ Drills and Navigated Disc Prep and Interbodies for U.S. with Mazor™ Robotic Guidance System Medtronic plc (NYSE: MDT) announced that the U.S. Food and Drug Administration (FDA) has cleared the use of navigated interbody and Midas Rex™ high...
About Medtronic Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic emp
Read more →MDTMedtronic's OsteoCool™ Procedure Shows Significant, Swift Pain Relief and Sustained Improvement for Cancer Patients Medtronic plc (NYSE: MDT) today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation (RFA) ...
DUBLIN , Dec. 15, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced the release of outcomes in the first 100 patients treated with the OsteoCool™ Radiofrequency Ablation (RFA) System in the OPuS One Clinical Study (as referenced below) – the largest, prospective stu
Read more →MDTDocument NEWS RELEASE Contacts Marguerite Copel Ryan Weispfenning Public Relations Investor Relations +1-203-214-8243 +1-763-505-4626
Contacts Marguerite Copel Ryan Weispfenning Public Relations Investor Relations +1-203-214-8243 +1-763-505-4626 SEAN SALMON NAMED EVP PRESIDENT CARDIOVASCULAR PORTFOLIO CONTINUES AS EVP PRESIDENT DIABETES OPERATING UNIT DUBLIN - December 14, 2020 - Medtronic plc (NYSE
Read more →MDTMedtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2021 The board of directors of Medtronic plc (NYSE: MDT) on Friday, December 11, 2020, approved the fiscal year 2021 third quarter cash dividend of $0.58...
DUBLIN , Dec. 14, 2020 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE: MDT ) on Friday, December 11, 2020 , approved the fiscal year 2021 third quarter cash dividend of $0.58 per ordinary share. This quarterly declaration is consistent with the dividend announcemen
Read more →MDTSean Salmon Named EVP & President Cardiovascular Portfolio; Continues as EVP & President Diabetes Operating Unit Medtronic plc (NYSE:MDT) announced today that Sean Salmon, Executive Vice President and President, Diabetes Operating Unit has been named Executive...
DUBLIN , Dec. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) announced today that Sean Salmon , Executive Vice President and President, Diabetes Operating Unit has been named Executive Vice President and President, Cardiovascular Portfolio effective January 1 . Salmon will a
Read more →MDTMedtronic Launches the First and Only Pediatric and Neonatal Acute Dialysis Machine in the U.S. Medtronic plc (NYSE:MDT) today announced the U.S. commercial launch of the Carpediem™ Cardio-Renal Pediatric Dialysis Emergency Machine. Following...
DUBLIN , Dec. 8, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced the U.S. commercial launch of the Carpediem™ Cardio-Renal Pediatric Dialysis Emergency Machine. Following the U.S. Food and Drug Administration's (FDA) marketing authorization, granted earlier this y
Read more →MDTMedtronic SVP of Strategy Mike Weinstein to Speak at Evercore ISI Healthcare Conference Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Evercore ISI 3rd Annual...
DUBLIN , Dec. 1, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it will participate virtually in the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020 . Mike Weinstein , senior vice president of
Read more →MDTMedtronic EVP & President of Cardiovascular Portfolio Mike Coyle to Speak at Piper Sandler Healthcare Conference Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Piper Sandler 32nd Annual...
DUBLIN , Nov. 30, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it will participate virtually in the Piper Sandler 32nd Annual Healthcare Conference on Wednesday, December 2, 2020 . Mike Coyle , executive vice president
Read more →MDTMedtronic and the Medtronic Foundation Expand COVID-19 Support to More Than $46 Million USD With the pandemic surging across the globe and food insecurity on the rise, Medtronic and the Medtronic Foundation today announced an additional $3.8 ...
DUBLIN and MINNEAPOLIS , Nov. 30, 2020 /PRNewswire/ -- With the pandemic surging across the globe and food insecurity on the rise, Medtronic and the Medtronic Foundation today announced an additional $3.8 million commitment to provide healthcare worker support and protection, men
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS SECOND QUARTER FISCAL 2021 FINANCIAL RESULTS Q2 R
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS SECOND QUARTER FISCAL 2021 FINANCIAL RESULTS Q2 Revenue of $7.6 Billion Decreased 0.8% Reported and 1.5% Organic Q2 GAAP Diluted EPS of $
Read more →MDTMedtronic Reports Second Quarter Fiscal 2021 Financial Results Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2021, which ended October 30, 2020. The company...
- Q2 Revenue of $7.6 Billion Decreased 0.8% Reported and 1.5% Organic - Q2 GAAP Diluted EPS of $0.36 ; Q2 Non-GAAP Diluted EPS of $1.02 DUBLIN , Nov. 24, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced financial results for its second quarter of fiscal year 2021
Read more →MDTMedtronic to Announce Financial Results for its Second Quarter of Fiscal Year 2021 Medtronic plc (NYSE:MDT) announced today that it will report financial results for its second quarter of fiscal year 2021 on Tuesday, November 24,...
DUBLIN , Nov. 17, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) announced today that it will report financial results for its second quarter of fiscal year 2021 on Tuesday, November 24, 2020 . A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST)
Read more →MDTThe New England Journal of Medicine: Medtronic Cryoablation is a Superior Treatment Option for Symptomatic Paroxysmal Atrial Fibrillation Compared to Drug Therapy Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First...
DUBLIN , Nov. 16, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced that the primary results of the Medtronic-sponsored STOP AF First clinical trial have been published in the New England Journal of Medicine (NEJM) . Results
Read more →MDTMedtronic Completes Acquisition of Medicrea Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has completed its friendly tender offer for France-based...
DUBLIN , Nov. 16, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced that it has completed its friendly tender offer for France -based Medicrea International (Euronext Growth Paris: FR0004178572 – ALMED Medicrea; OTCQX Best M
Read more →MDTMedtronic Ranked as a Leading Sustainability Company Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced that it has been recognized as one of the world's leading...
DUBLIN , Nov. 13, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced that it has been recognized as one of the world's leading companies for sustainability with its inclusion in the Dow Jones Sustainability North America Inde
Read more →MDTMedtronic Launches InPen™ with Real-Time Guardian™ Connect CGM Data -- the First Integrated Smart Insulin Pen for People with Diabetes on MDI Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the launch of InPen™ integrated with real-time1 Guardian Connect™ ...
The integration of real-time CGM data into the smart insulin pen app is a result of the addition of Companion Medical's InPen to the Medtronic portfolio, as of September 2020 . The acquisition enables Medtronic to serve more people — regardless of how they prefer their insulin to
Read more →MDTMedtronic Expands ENT Portfolio with FDA Clearance of NIM Vital™ Next Generation Intraoperative Nerve Monitoring System and Acquisiton of Ai Biomed Corp. Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) 510(k)...
The company also announced further enhancement of its ENT portfolio with the recent acquisition of privately-held Ai Biomed Corp., maker of the PTeye™ parathyroid detection system. The only probe-based technology of its kind, 5 the PTeye system is designed to help confirm parathy
Read more →MDTMedtronic Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obstruction Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval...
DUBLIN , Oct. 26, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for the Abre™ venous self-expanding stent system. This device is indicated for use in the i
Read more →MDTPatients Report Superior, Sustained and Profound Back Pain Relief at 12 Months with DTM™ Spinal Cord Stimulation Therapy Using the Medtronic Intellis™ Platform Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced statistically significant 12-month results from a large,...
DUBLIN , Oct. 20, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced statistically significant 12-month results from a large, multicenter randomized controlled trial (RCT) that further validate the superiority of DTM™ Spinal
Read more →MDTNine-Month Results from Medtronic IN.PACT BTK Study Presented in Late-Breaking Clinical Trial Sessions at TCT Connect Annual Meeting Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first-ever results from the IN.PACT BTK Study, a feasibility...
Feasibility Study of Medtronic Drug-Coated Balloon Technology for Challenging Below-the-Knee Disease Shows Promise in Patients with Critical Limb Ischemia DUBLIN , Oct. 18, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced
Read more →MDTMedtronic Announces Partnership with The Foundry to Develop Innovative Mitral Valve Repair Technology Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced a partnership with The Foundry – a medical device company...
Half Moon Medical's Technology Now Ready for Evaluation in Early Feasibility Study DUBLIN , Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced a partnership with The Foundry – a medical device company incubator – da
Read more →MDTMedtronic Named One of America's Most JUST Companies by Forbes and JUST Capital Medtronic plc (NYSE:MDT), the global leader in medical technology, has been named one of America's most JUST companies, ranking 29th overall on the...
DUBLIN , Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, has been named one of America's most JUST companies, ranking 29th overall on the ' Forbes JUST 100' list for 2021 and first in its industry category of Healthcare Equipment
Read more →MDTMedtronic Launches Head-to-Head TAVR Study Comparing the Evolut™ TAVR Platform Against the Edwards SAPIEN Valve in Small Annulus Patients Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced it will begin a randomized, head-to-head study comparing two ...
Medtronic Also Begins Feasibility Study of Evolut TAVR System in Moderate and Asymptomatic Aortic Stenosis Patients DUBLIN , Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in structural heart therapies, today announced it will begin a randomized, head-
Read more →MDTMedtronic Outlines Growth Strategy at Biennial Investor Day Medtronic plc (NYSE: MDT), the global leader in medical technology, will outline today the company's strategy for driving accelerated revenue growth...
Company Raises Revenue Growth Outlook Highlights Deep and Broad Pipeline and Technology Platforms DUBLIN , Oct. 14, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, will outline today the company's strategy for driving accelerated revenu
Read more →MDTMedtronic 2020 Integrated Performance Report Shares Goal of Carbon Neutrality by FY30, Achievement of 100% Gender Pay Equity in the U.S., and Progress on COVID-19 Response Medtronic plc (NYSE:MDT) today released its fiscal year 2020 (FY20) Integrated Performance Report: Putting Purpose Into Action. The report shares the ...
Report Outlines Environmental, Social, and Governance (ESG) Topics Critical to the Company and Its Stakeholders DUBLIN , Oct. 13, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today released its fiscal year 2020 (FY20) Integrated Performance Report: Putting Purpose Into Action
Read more →MDTMedtronic Donates Nearly $1 Million in Personal Protective Equipment to International Medical Corps for COVID-19 Response Efforts Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has donated nearly $1 million worth of personal protective ...
DUBLIN , Oct. 9, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced that it has donated nearly $1 million worth of personal protective equipment (PPE) to relief organization International Medical Corps to support its ongoing
Read more →MDTMedtronic Announces Adaptix™ Interbody System, the First Navigated Titanium Cage with Titan nanoLOCK™ Surface Technology Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the U.S. launch of Adaptix™ Interbody System, the first navigated...
DUBLIN , Oct. 7, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the U.S. launch of Adaptix™ Interbody System, the first navigated titanium implant with Titan nanoLOCK™ Surface Technology, a proprietary blend of surface te
Read more →MDTMedtronic Announces First Patient Implanted in ELITE Study of InterStim™ Micro Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient was implanted in its ELITE study of the...
DUBLIN , Oct. 6, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the first patient was implanted in its ELITE study of the InterStim™ Micro system — the only study of a rechargeable sacral neurostimulation (SNS) system to
Read more →MDTOmar Ishrak to Retire as Medtronic Executive Chairman and Chairman of the Board; Geoff Martha to Succeed Ishrak as Chairman of the Board, Effective December 11, 2020 Medtronic plc (NYSE:MDT) today announced that Omar Ishrak has decided not to stand for re-election at the Annual General Meeting in December and will ...
DUBLIN , Oct. 6, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) today announced that Omar Ishrak has decided not to stand for re-election at the Annual General Meeting in December and will retire as Executive Chairman and Chairman of its Board of Directors effective December 11,
Read more →MDTMedtronic Announces Virtual 2020 Institutional Investor and Analyst Event and Webcast Medtronic plc (NYSE:MDT) announced today that the company will host its biennial Institutional Investor and Analyst Event on Wednesday, October 14,...
DUBLIN , Oct. 5, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ) announced today that the company will host its biennial Institutional Investor and Analyst Event on Wednesday, October 14, 2020 , from 8:00 a.m. to approximately 2:00 p.m. Eastern Daylight Time ( 7:00 a.m. to approx
Read more →MDTMedtronic Resolute Onyx™ Drug Eluting Stent (DES) First to Receive One-Month DAPT Labeling in the U.S. with Expanded Indication for High Bleeding Risk Patients Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval...
DUBLIN , Oct. 1, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for new one-month of dual-antiplatelet therapy (DAPT) labeling with an expanded indication f
Read more →MDTMedtronic to Acquire Avenu Medical Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the planned acquisition of Avenu Medical, a privately held medical ...
Avenu's Percutaneous Fistula Creation Technology Will Strengthen the Medtronic Peripheral Vascular Access Portfolio and Reinforce Medtronic's Commitment to Improving Outcomes for Patients with End-Stage Renal Disease DUBLIN , Sept. 30, 2020 /PRNewswire/ -- Medtronic plc (NYSE: M
Read more →MDTMedtronic Announces Closing of Public Offering of €6.25 Billion of Senior Notes and Redemption of Outstanding Senior Notes Medtronic plc (the Company ) (NYSE:MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ( Medtronic Luxco ) has...
DUBLIN , Sept. 29, 2020 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT ) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ("Medtronic Luxco") has closed a registered public offering (the "Offering") of €1,250,000,000 principal amount of
Read more →MDTMedtronic Gets Affirmation of Key Sacral Neuromodulation Patent Medtronic (NYSE:MDT) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the...
DUBLIN , Sept. 25, 2020 /PRNewswire/ -- Medtronic (NYSE: MDT ) has won an important victory in a patent dispute over intellectual property for its sacral neuromodulation device family, the InterStim™ systems. The Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Tradema
Read more →MDTMedtronic Announces Pricing of €6.25 Billion of Senior Notes Medtronic plc (the Company ) (NYSE: MDT) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ( Medtronic Luxco ), has ...
DUBLIN , Sept. 24, 2020 /PRNewswire/ -- Medtronic plc (the "Company") (NYSE: MDT ) announced today that its wholly-owned subsidiary, Medtronic Global Holdings S.C.A. ("Medtronic Luxco"), has priced an offering (the "Offering") of €1,250,000,000 principal amount of 0.000% senior n
Read more →MDTMedtronic Evaluates Insertable Cardiac Monitor in Identifying Patients at High Risk of Worsening Heart Failure Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced first enrollments in the ALLEVIATE-HF clinical trial which will...
DUBLIN , Sept. 23, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced first enrollments in the ALLEVIATE-HF clinical trial which will evaluate the ability of its Reveal LINQ™ Insertable Cardiac Monitor (ICM) in identifying pa
Read more →MDTMedtronic Receives FDA Breakthrough Device Designation for TYRX Driveline Wrap Device Medtronic plc (NYSE:MDT), the global leader in medical technology, has received Breakthrough Device Designation status from the U.S. Food and Drug...
DUBLIN , Sept. 22, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA) for the TYRX™ Absorbable Antibacterial Driveline Wrap, which is intend
Read more →MDTMedtronic TYRX™ Absorbable Antibacterial Envelope Is Cost Effective for Patients at Increased Risk of Infections Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from the landmark WRAP-IT study, showing the TYRX™...
DUBLIN , Sept. 16, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced new data from the landmark WRAP-IT study, showing the TYRX™ Absorbable Antibacterial Envelope (TYRX Envelope) is cost effective for patients at increased r
Read more →MDTMedtronic CEO Geoff Martha to Speak at Morgan Stanley Global Healthcare Conference Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate virtually in the Morgan Stanley 18th Annual...
DUBLIN , Sept. 11, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it will participate virtually in the Morgan Stanley 18th Annual Global Healthcare Conference on Monday, September 14, 2020 . Geoff Martha , Medtronic chie
Read more →MDTMedtronic Study Finds Opioid-Induced Respiratory Depression in the Hospital More Common and Costly Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the publication of primary data from PRODIGY (PRediction of...
DUBLIN , Sept. 10, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced the publication of primary data from PRODIGY (PRediction of Opioid-induced respiratory Depression In patients monitored by capnoGraphY), a Medtronic-sponso
Read more →MDTMedtronic Receives Breakthrough Device Designation from FDA, Begins Early Feasibility Study for Investigational Intrepid™ Transcatheter Valve System for the Treatment of Tricuspid Valve Regurgitation Medtronic plc (NYSE:MDT), a global leader in structural heart therapies, today announced U.S. Food and Drug Administration (FDA) approval of an early ...
DUBLIN , Sept. 9, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), a global leader in structural heart therapies, today announced U.S. Food and Drug Administration (FDA) approval of an early feasibility study (EFS) of the Intrepid™ Transcatheter Tricuspid Valve Replacement (TTVR)
Read more →MDTMedtronic EVP & CFO Karen L. Parkhill To Participate in the Wells Fargo Securities 2020 Virtual Healthcare Conference Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it will participate in the Wells Fargo Securities 2020 Virtual...
DUBLIN , Sept. 4, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it will participate in the Wells Fargo Securities 2020 Virtual Healthcare Conference on Thursday, September 10, 2020 . Karen Parkhill , executive vice pres
Read more →MDTMedtronic Announces FDA Approval for MiniMed™ 770G Insulin Pump System with Smartphone Connectivity for People with Type 1 Diabetes Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval...
DUBLIN , Sept. 1, 2020 /PRNewswire/ -- Medtronic plc (NYSE: MDT ), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval of its MiniMed™ 770G hybrid closed loop system. This newest insulin pump system offers the
Read more →MDTMedtronic Cryoablation Superior to Drug Therapy for Symptomatic Paroxysmal Atrial Fibrillation
Medtronic's recent clinical trials demonstrate that cryoablation is more effective than antiarrhythmic drug therapy for treating symptomatic paroxysmal atrial fibrillation. The STOP AF First trial showed a 75% success rate in maintaining freedom from atrial fibrillation with cryoablation, compared to 45% with drugs. Additionally, the Cryo-FIRST trial highlighted significant improvements in patients' quality of life after cryoablation treatment.
Read more →MDTMedtronic Reports First Quarter Financial Results
Medtronic plc reported its first quarter financial results for fiscal year 2021, revealing a 13% decrease in worldwide revenue to $6.507 billion. Adjusted for various factors, the organic revenue decline was approximately 17%. Despite the challenges posed by the COVID-19 pandemic, the company noted a recovery in procedure volumes and expressed optimism for future growth. However, it refrained from providing formal financial guidance due to ongoing uncertainties.
Read more →MDTDocument NEWS RELEASE Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS Q1 Revenue of $6.
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS Q1 Revenue of $6.5 Billion Decreased 13% Reported and Approximately 17% Organic Q1 GAAP Diluted EPS of $0
Read more →MDTMedtronic Board Appoints Kevin Lofton as a New Director
Medtronic plc has appointed Kevin Lofton as an independent director, effective September 15, 2020. Lofton, a seasoned healthcare executive, will serve on the Audit, Compensation, and Quality committees. His extensive experience in leading major hospital systems and focus on healthcare equity is expected to enhance the board's perspective.
Read more →MDTMedtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2021
Medtronic plc has announced a cash dividend of $0.58 per share for the second quarter of fiscal year 2021, marking a 7% increase from the previous year. This dividend is part of the company's ongoing commitment to shareholder returns and aligns with its previous announcements. The payment is scheduled for October 16, 2020, to shareholders on record by September 25, 2020.
Read more →MDTMedtronic Evolut TAVR System Receives Updated U.S. Labeling Revising Precaution for Treatment of Low-Risk Patients with Bicuspid Aortic Stenosis
Medtronic announced that the FDA has approved updated labeling for its Evolut TAVR system, allowing low-risk patients with bicuspid aortic stenosis to be considered for treatment. The revised guidelines include recommendations for heart teams assessing candidates based on anatomical characteristics and clinical data. Positive outcomes from recent studies support the system's effectiveness in this patient population.
Read more →MDTMedtronic Begins Post-Market, Real-World Study of the InterStim™ Micro System
Medtronic has initiated the ELITE study to evaluate the InterStim Micro system for sacral neuromodulation therapy. This prospective, multicenter study aims to confirm the long-term safety and efficacy of the device in treating overactive bladder, fecal incontinence, and non-obstructive urinary retention. The study will enroll 160 participants across various countries and follow them for two years.
Read more →MDTMedtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2021
Medtronic plc will announce its financial results for the first quarter of fiscal year 2021 on August 25, 2020. A news release will be issued at 5:45 a.m. CDT, followed by a webcast at 7:00 a.m. CDT to discuss the results. The company also outlined plans for future quarterly reports later in the fiscal year.
Read more →MDTMedtronic to Acquire Smart Insulin Pen Company Companion Medical
Medtronic has announced its acquisition of Companion Medical, the maker of the InPen, a smart insulin pen system. This acquisition aims to enhance Medtronic's offerings for diabetes management, particularly for individuals using multiple daily injections. The deal is expected to close within one to two months and is projected to be neutral to Medtronic's earnings in the current fiscal year. The integration of InPen with Medtronic's technology is anticipated to improve dosing advice for users.
Read more →MDTMedtronic Announces Comprehensive U.S. Launch of New InterStim™ Micro Neurostimulator
Medtronic has launched its FDA-approved InterStim Micro neurostimulator for sacral neuromodulation therapy in the U.S., with the first implant performed at Cleveland Clinic. This device aims to improve bladder and bowel control for patients suffering from overactive bladder (OAB) and fecal incontinence (FI). The launch is supported by extensive clinical data and aims to enhance the quality of life for millions of affected adults.
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL RESULTS ANNO
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2020 FINANCIAL RESULTS ANNOUNCES DIVIDEND INCREASE Q4 Revenue of $6.0 Billion Decreased 26% Reported and 2
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC PROVIDES UPDATE ON COVID-19 PANDEMIC RESPONSE AND IMPACT Company A
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC PROVIDES UPDATE ON COVID-19 PANDEMIC RESPONSE AND IMPACT Company Actively Supporting Its Employees, Customers, and Communities Delayed Procedures
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS Revenue of $7.7 Billion In
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS Revenue of $7.7 Billion Increased 2.3% Reported and 2.6% Organic GAAP Diluted EPS of $1.42 Increased 51%
Read more →MDTErika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS Revenue of $7.7 Billion I
Contacts Erika Winkels Ryan Weispfenning Public Relations Investor Relations +1-763-526-8478 +1-763-505-4626 MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS Revenue of $7.7 Billion Increased 3.0% Reported and 4.1% Organic GAAP Diluted EPS of $1.01 Non-GAAP Dilu
Read more →MDTFrancesca DeMartino Ryan Weispfenning Public Relations Investor Relations +1-763-505-2029 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS Revenue of $7.5 Bil
Contacts: Francesca DeMartino Ryan Weispfenning Public Relations Investor Relations +1-763-505-2029 +1-763-505-4626 MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS DUBLIN - August 20, 2019 - Medtronic plc (NYSE:MDT) today announced financial results for its first
Read more →MDTFrancesca DeMartino Public Relations +1-763-505-2029 Ryan Weispfenning Investor Relations +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Announces the Early Results of its Cash Tender Offers for u
FOR IMMEDIATE RELEASE Medtronic Announces the Early Results of its Cash Tender Offers for up to $5.525 billion of Certain Outstanding Debt Securities Issued by Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A. DUBLIN July 10, 2019 - Medtr
Read more →MDTFrancesca DeMartino Ryan Weispfenning Public Relations Investor Relations +1-763-505-2029 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Announces the Upsizing of its Maximum Tender Offer to up to
FOR IMMEDIATE RELEASE Medtronic Announces the Upsizing of its Maximum Tender Offer to up to $4.35 billion for Certain Outstanding Debt Securities Issued by Medtronic, Inc., Medtronic Global Holdings S.C.A. and Covidien International Finance S.A. DUBLIN June 25, 2019 Medtronic p
Read more →MDTFrancesca DeMartino Ryan Weispfenning Public Relations Investor Relations +1-763-505-2029 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FISCAL YEAR AND FOURTH QUARTER 2019 FINANCIAL RESUL
Contacts: Francesca DeMartino Ryan Weispfenning Public Relations Investor Relations +1-763-505-2029 +1-763-505-4626 MEDTRONIC REPORTS FISCAL YEAR AND FOURTH QUARTER 2019 FINANCIAL RESULTS DUBLIN - May 23, 2019 - Medtronic plc (NYSE: MDT) today announced financial
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC BOARD APPOINTS ANDREA J. GOLDSMITH, PH.D. AS A
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC BOARD APPOINTS ANDREA J. GOLDSMITH, PH.D. AS A NEW DIRECTOR DUBLIN - March 14, 2019 - Medtronic plc (NYSE:MDT) today announced that its Board
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Announces Closing of Public Offering of Senior Notes; Acceptan
FOR IMMEDIATE RELEASE Medtronic Announces Closing of Public Offering of Senior Notes; Acceptance of Tendered Notes; and Redemption of Certain Senior Notes DUBLIN March 7, 2019 - Medtronic plc (the Company ) (NYSE: MDT) today announced that its wholly-owned subsidiary Medtronic
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Announces the Upsizing of its Maximum Tender Offers for Certai
FOR IMMEDIATE RELEASE Medtronic Announces the Upsizing of its Maximum Tender Offers for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A. DUBLIN March 4, 2019 Medtronic plc (the Company ) (NYSE: MDT) today announced the upsizi
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Announces Cash Tender Offer for Certain Outstanding Debt Secur
FOR IMMEDIATE RELEASE Medtronic Announces Cash Tender Offer for Certain Outstanding Debt Securities Issued by Medtronic, Inc. and Covidien International Finance S.A. DUBLIN February 20, 2019 - Medtronic plc (the Company ) (NYSE: MDT) today announced the commencement of a cash
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS Revenue of $7.5 Billi
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS DUBLIN - November 20, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its seco
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS Revenue of $7.4 Billio
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS DUBLIN - August 21, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its first q
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2018 FINANCIAL RESULTS DUBLIN - May 24, 2018 - Medtronic plc (NYSE: MDT) today announced financial res
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS Revenue of $7.4 Billio
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS DUBLIN - February 20, 2018 - Medtronic plc (NYSE: MDT) today announced financial results for its third
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE BOB WHITE NAMED EXECUTIVE VICE PRESIDENT AND PRESIDENT OF MEDTRONIC'S MI
Exhibit 99.1 NEWS RELEASE Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 BOB WHITE NAMED EXECUTIVE VICE PRESIDENT AND PRESIDENT OF MEDTRONIC'S MINIMALLY INVASIVE THERAPIES GROUP; CHRIS LEE TO AS
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS Revenue of $7.1 Billi
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS DUBLIN - November 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its seco
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC ANNOUNCES PRELIMINARY SECOND QUARTER REVENUE Preliminary Reven
Exhibit 99.1 NEWS RELEASE Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC ANNOUNCES PRELIMINARY SECOND QUARTER REVENUE DUBLIN - November 8, 2017 - Medtronic plc (NYSE: MDT) today announc
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS Revenue of $7.390 Bill
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS DUBLIN - August 22, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its first q
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS DUBLIN - May 25, 2017 - Medtronic plc (NYSE: MDT) today announced financial res
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS Revenue of $7.3 Billio
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS THIRD QUARTER FINANCIAL RESULTS DUBLIN - February 21, 2017 - Medtronic plc (NYSE: MDT) today announced financial results for its third
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS Revenue of $7.3 Billi
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS SECOND QUARTER FINANCIAL RESULTS DUBLIN - November 22, 2016 -Medtronic plc (NYSE: MDT) today announced financial results for its secon
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS Revenue of $7.2 Billio
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS FIRST QUARTER FINANCIAL RESULTS DUBLIN - August 25, 2016 - Medtronic plc (NYSE: MDT) today announced financial results for its first q
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2016 FINANCIAL RESULTS
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC REPORTS FOURTH QUARTER AND FISCAL YEAR 2016 FINANCIAL RESULTS DUBLIN - May 31, 2016 - Medtronic plc (NYSE: MDT) today announced financial res
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC WELCOMES KAREN L. PARKHILL AS ITS NEW CHIEF FINANCIAL OFFICER
FOR IMMEDIATE RELEASE MEDTRONIC WELCOMES KAREN L. PARKHILL AS ITS NEW CHIEF FINANCIAL OFFICER Gary Ellis to Remain on Medtronic Executive Committee Until Retirement in Fiscal Year 2017 DUBLIN May 4, 2016 Medtronic plc (NYSE: MDT) announced today the appointment of Karen L. P
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE MEDTRONIC ANNOUNCES THE EARLY RESULTS AND UPSIZING OF ITS CASH TENDER OF
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 MEDTRONIC ANNOUNCES THE EARLY RESULTS AND UPSIZING OF ITS CASH TENDER OFFER FOR CERTAIN OUTSTANDING DEBT SECURITIES ISSUED BY MEDTRONIC, INC. AND COVIDIE
Read more →MDTFernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 FOR IMMEDIATE RELEASE Medtronic Announces Cash Tender Offer for Up to $2.75 Billion Aggregate
Contacts: Fernando Vivanco Ryan Weispfenning Public Relations Investor Relations +1-763-505-3780 +1-763-505-4626 Medtronic Announces Cash Tender Offer for Up to $2.75 Billion Aggregate Purchase Price of Certain Outstanding Debt Securities Issued by Medtronic, Inc. a
Read more →Competitive Position
How MDT ranks across every disease it competes inCompetitive Position is a premium feature
See how MDT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial